AB Science is developing its lead compound masitinib simultaneously in veterinary and human medicine. Masitinib is an oral tyrosine kinase inhibitor that targets a limited number of key kinases implicated in various cancers. Its main cellular target is the mast cell, which is capable of releasing large amounts of pro-inflammatory mediators with a consequence of triggering and sustaining an inflammatory response. Owing to its broad mechanisms of action masitinib is developed in various indications, in the fields of oncology and inflammatory disease, in both dogs and cats.

In the spirit of AB Science’s commitment of sharing information with the veterinary community and updating you with most recent developments from our own varied veterinary research program as well as findings communicated from external collaborators and independent practitioners, we have created this information pack of masitinib-related publications and other sources of printed information. It is intended to provide a convenient one-stop reference source, covering peer-reviewed journal articles, meeting abstracts, conference proceeding manuscripts, press articles, and press-releases communicated by international news agencies. With periodic updates we hope to help keep the veterinary community abreast of the latest clinical developments, safety-related issues, and highlight emerging new therapeutic directions of relevance to the veterinary application of masitinib.

Everyone knows that a picture is worth 1000 words, and this saying has never been truer than when comparing before and after images from successful treatment of tumors or inflammatory conditions. However, in an effort to keep this information pack to a manageable size, the presentation of materials rich in photographic evidence and graphical data has been minimized. Many examples of such material, including poster presentations and videos, can be found on the AB Science website (www.ab-science.com), and also on the scientific book ‘The Efficacy of Targeted Therapy in Veterinary Medicine’, which is available on demand (contact@ab-science.com).

From the following summary of publications it can be seen that masitinib holds therapeutic potential for both veterinary oncological and immune-mediated conditions (note that this is a compendium of veterinary communications only; for information on publications relating to human medicine please visit the AB Science website - www.ab-science.com). Emerging clinical evidence, generated largely through the research of veterinary clinical investigators, continues to expand the range of canine or feline diseases for which masitinib may be of therapeutic benefit, either as a single agent or in combination with existing therapies. As such, we believe that masitinib is likely to become an increasingly important tool in the veterinarian’s therapeutic armamentarium.

Masitinib (Masivet® and Kinavet CA-1®) can only be obtained by practitioners of veterinary medicine located in countries for which it has received appropriate authorization. Masitinib is available directly from the AB Science website following client registration. The process is very simple and only requires a few minutes of your time.

Pet owners are advised to contact their local Veterinary Surgeon.

For more information visit www.ab-science.com or contact us at masivet@ab-science.com.
# TABLE OF CONTENT

1  *Foreword* ........................................................................................................................................... 2

2  *Introduction* ......................................................................................................................................... 6

3  *Recent news and upcoming events* ................................................................................................. 10

   3.1  Publications new to this issue .................................................................................................. 10

   3.2  Future publications and congress presentations .................................................................... 10

   3.3  Recent newsworthy events – AB Science press releases ...................................................... 11

4  *Publications on masitinib basic research* ......................................................................................... 17

   4.1  Masitinib (AB1010), A Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT 17

   4.2  Masitinib as a Chemosensitizer of Canine Tumor Cell Lines ............................................. 18

   4.3  Gain-of-Function Mutations in the Extracellular Domain of KIT are Common in Canine Mast Cell Tumors ......................................................................................................... 18

   4.4  A tyrosine kinase inhibitor targeting c-kit for chronic inflammatory diseases involving mast cells ........................................................................................................................................... 19

   4.5  Masitinib is a Chemosensitizer of Canine Tumor Cell Lines ................................................... 20

5  *Canine mast cell tumor* ...................................................................................................................... 21

   5.1  Masitinib in Canine Mast Cell Disease .................................................................................... 21

   5.2  Evaluation of 12- and 24-Month Survival Rates After Treatment with Masitinib in Dogs with Nonresectable Mast Cell Tumors ...................................................................... 22

   5.3  Masitinib is Safe and Effective for the Treatment OF Canine Mast Cell Tumors ............... 23

   5.4  Fifty Months and Counting: Case Studies Exemplifying the Long-Term Survival of Masitinib in Dogs with Non-Resectable Grade II Mast Cell Tumors ...................................... 24

   5.5  First-Line and Rescue Therapy with Masitinib Integrated Protocols for Canine Cutaneous Mast Cell Tumors. .................................................................................................. 25

   5.6  Impact of Masitinib on Metastatic Mast Cell Tumors and on the Emergence of Metastasis from Non-Metastatic Tumors ........................................................................... 26

   5.7  Masitinib in the Treatment Canine Grade 2/3 Mast Cell Tumors That Only Express WT c-Kit ........................................................................................................................................... 27

   5.8  Short-Term Tumor Response to Tyrosine Kinase Inhibitors Versus Long-Term Survival in Mast Cell Tumors: Follow-Up Data from a Pivotal Field Study with Masitinib .............................................................................................................................. 28

   5.9  Response to Treatment with Masitinib of Chemotherapy Resistant, Metastasized, Canine Cutaneous Grade 2 and 3 Mast Cell Tumors: A Pilot Study ........................................... 29

   5.10 Evaluation of Masitinib in the Treatment of Canine Mast Cell Tumors: Long-Term Follow-Up Efficacy Data from Phase 3 Clinical Study ......................................................... 30
Assessment of Response to the Treatment with Masitinib (Masivet) of Chemotherapy Resistant, Grade 2 and 3, Metastasized Canine Cutaneous Mast Cell Tumors. Report of Four Cases .......................................................... 31

Masitinib is Effective in the Treatment Canine Grade 2/3 Mast Cell Tumours that only Express WT c-Kit .................................................................................................................. 32

Masitinib Reduces the Onset of Metastasis and Improves Long-Term Survival in Dogs with Measurable Grade 2 and Grade 3 Mast Cell Tumours. ........................................... 33

A Novel c-KIT Inhibitor (AB1010) Shows Therapeutic Potential in Dog Mast Cell Tumors (DMCT) ................................................................................................................... 34

Positive Response in the Treatment of Epitheliotropic T-Cell Lymphoma (Mycosis Fungoides) with Masitinib .................................................................................................... 35

Masitinib for Maintenance Chemotherapy of Two Dogs with T-Cell Multicentric Lymphoma ........................................................................................................................... 36

A c-Kit Inhibitor (Masivet®) Shows Therapeutic Potential in Dog Neurofibrosarcoma37

Evaluation of the Receptor Tyrosine Kinase Inhibitor, Masitinib Mesylate, in Canine Hemangiosarcoma Cell Lines ........................................................................................................... 38

Masitinib, oral tyrosine kinase inhibitor, in the treatment of advanced melanoma: preclinical proof-of-concept and phase 1/2/3 study designs .................................................. 39

The Cytotoxic Effect Of Masitinib (Masivet8) on a Canine Leukemia Cell Line does not Result from Inhibition of the ABC-Transporters P-Gp and MRP-1 ............................... 40

Evaluation of Safety of Masitinib in Combination with Doxorubicin in Advanced Canine Tumors ...................................................................................................................... 41

Evaluation of Safety of Masitinib in Combination with Carboplatin in Advanced Canine Tumors ................................................................................................................... 42

Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial’ ................................................................. 43


The Tyrosine Kinase Inhibitor Masitinib (Masivet®) is Effective for Treatment of Atopic Dermatitis in Dogs ........................................................................................................... 45

Masitinib for the Treatment of Canine Atopic Dermatitis: A Pilot Study .......................... 46

Efficacy and Safety of Masitinib on the Treatment of Atopic Dermatitis in Dogs............ 47

Safety of Masitinib Mesylate in Healthy Cats ................................................................ 48

Pharmacokinetics of Masitinib in Cats ............................................................................ 49

A Randomized, Blinded, Placebo-Controlled Study of the Tyrosine Kinase Inhibitor Masitinib for Treatment of Experimental Feline Asthma .................................................. 50
8.4 Masitinib Decreases Cell Proliferation, Promotes Apoptosis and Inhibits PDGF-Induced Phosphorylation of PDGF Receptor in Vaccine-Associated Sarcoma Cells .......... 51
8.5 Evaluation of the Receptor Tyrosine Kinase Inhibitor, Masitinib Mesylate, in Feline Vaccine Associated Sarcoma Cell Lines and Healthy Cats ........................................ 52

9 Miscellaneous canine and feline treatments ................................................................. 53

9.1 Masitinib – a targeted therapy with applications in veterinary oncology and inflammatory diseases ........................................................................................................ 53
9.2 New Therapeutic Options in Veterinary Oncology: Tyrosine Kinase Inhibitors .......... 54
9.3 Masitinib – The Efficacy of Targeted Therapy in Veterinary Medicine .................... 55
9.4 Targeted Therapy with Masitinib in Canine and Feline Tumours in Two European Veterinary Oncology Centres ............................................................................. 56
9.5 Drug-Induced Minimal Change Nephropathy in a Dog ............................................ 57
9.6 Clinical Trial on the Efficacy of Masitinib in Canine IBD ........................................... 57

10 List of Appendices ........................................................................................................ 58
INTRODUCTION

Adapted from the proceedings manuscript ‘New Therapeutic Options in Veterinary Oncology: Tyrosine Kinase Inhibitors’, that accompanied Dr Albert Ahn’s invited presentation at the 2011 American College of Veterinary Internal Medicine Forum (June 15-18).

DEVELOPMENT OF MASITINIB

Masitinib was the first ever approved anti-cancer drug in veterinary medicine, receiving approval from the European Medicines Agency (EMA) in 2008 under the trade name Masivet®. Masitinib has also recently become obtainable in the United States under the trade name Kinavet CA-1®, having received conditional approval in December 2010 from the US Food and Drug Administration (FDA); its availability up to that point being limited to a personal importation program for veterinarians. Masitinib has been designed specifically to optimize its selectivity against just a few key tyrosine kinases that are implicated in various cancers (primarily KIT, PDGFR, and Lyn) while not inhibiting, at therapeutic doses, those tyrosine kinases or tyrosine kinase receptors attributed to possible toxicity. This degree of specificity contrasts with the TKIs of imatinib and toceranib, which inhibit a broader range of kinases as part of a more multi-targeted strategy; e.g. toceranib inhibits in excess of 50 kinases. Major targets of imatinib include ABL, KIT, and PDGFR; those of toceranib include KIT, PDGFR, vascular endothelial growth factor receptor 2 (VEGFR2), and Flt-3. While such multi-targeting can enhance a drug’s anticancer potency, this approach does appear to hold potential increased risk of higher toxicity. The atypically high selectivity of masitinib permits it to be administered at higher doses for a more potent therapeutic effect, whilst maintaining an acceptable level of tolerability; i.e. one can expect it to exhibit a better safety profile than multi-targeting TKIs.

To date masitinib has completed two pivotal phase III randomized controlled trials in veterinarian medicine; the first in MCT and the second in canine atopic dermatitis. A wealth of knowledge has been accumulated from its on- and off-label use in Europe, case studies that along with in-vitro preclinical research are driving further clinical development in numerous other cancers and as a chemosensitizer for standard chemotherapies. In addition to this, masitinib’s veterinary development program is acquiring knowledge for cat related disorders such as feline asthma and melanoma, including pharmacokinetic and toxicity preclinical studies. It is interesting to note that masitinib is being developed simultaneously in veterinary and human medicines, an uncommon approach that not only generates a large database of relevant experience but one that also recently helped accelerate a development program in human melanoma directly to a phase III randomized control trial, partly through the knowledge gained from treatment of canine MCT. In human medicine, masitinib currently has nine phase III studies initiated in various oncology and non-oncological conditions.

Among those tyrosine kinases associated with cancer development and progression, KIT has emerged as an attractive molecular target due to its over expression and/or constitutive activation being involved in the development of MCTs, gastrointestinal stromal tumors (GIST) and melanoma. Masitinib is perhaps the most specific inhibitor of wild-type and juxtamembrane-mutated KIT available, making these particularly relevant indications. Moreover, stem cell factor, the ligand of the KIT receptor, is a critical growth factor for mast cells, meaning masitinib’s strong inhibitory effect on KIT receptors makes it an effective anti mast cell agent. Evidence also indicates that recruitment of inflammatory cells, especially infiltration by mast cells, facilitates the growth and spread of cancers by producing molecules that enhance tumor invasiveness. Indeed, it has been shown that mast cells are
critical regulators of inflammation and immunosuppression in the tumor microenvironment. Therefore, reduction of the mast cell burden may prove to be of therapeutic benefit in restraining the growth of numerous cancers, even those without a direct association with mast cell proliferation. Complementing this KIT-related anti proliferative and pro-apoptosis action on mast cells, masitinib is also capable of regulating their activation through its targeting of Lyn, Fyn and Lck. Such down regulation of mast cell activity reduces the array of mediators released, including vascular endothelial growth factor (VEGF), which in turn is likely to disrupt as yet unidentified downstream signaling pathways and angiogenesis processes. Additionally, it is thought that inhibition of Lyn kinase activity also has potential benefits in defense against metastasis and drug-resistance. Masitinib’s inhibition of PDGFR kinase activity may result in direct tumor cell growth arrest and apoptosis if PDGFR is constitutively activated. In a more general sense, masitinib may also reduce angiogenesis and enhance chemotherapy sensitivity and availability at the tumor site through modulation of the tumor’s interstitial fluid pressure via inhibition of PDGFR-β. Moreover, it is established that mast cells are strongly implicated in a diverse range of non-oncology diseases, in part through their ability to release large amounts of pro-inflammatory mediators with subsequent triggering and sustainment of an inflammatory response. Thus, in addition to masitinib’s application as an anti-cancer treatment, inhibition of mast cells can be of therapeutic benefit to a large number of immune-mediated and neurological conditions.

Side effects typical associated with this therapeutic class are gastrointestinal toxicities, including diarrhea and vomiting. Such reactions are usually mild to moderate in severity, relatively short-lived, and tend to be transitory in nature, having a comparable frequency to untreated subjects after the first 3 months of treatment. Advantageously, these and other TKI-related adverse reactions normally spontaneously resolve upon cessation of treatment with no risk of withdrawal symptoms. However, TKIs do have a potential to induce adverse reactions that are unique unto themselves rather than class-effects and which can sometimes be of a serious nature; for example, ABL and VEGFR inhibition is associated with cardiac dysfunction, while PDGFR inhibition is possibly associated with hypoalbuminemia, and KIT inhibition is possibly related to neutropenia. Such reactions are the likely consequence of an inhibited kinase inadvertently affecting signaling pathways important for the correct function of untargeted cells. Here again then, is a good argument in favor of highly specific TKIs rather than ‘dirty’ multi-targeting, for reducing the risk of such unintended side-effects.

Regarding the increased possibility of protein loss syndrome (hypoalbuminemia) in dogs treated with masitinib, it was shown in the phase III canine atopic dermatitis study that any risk of harm can be greatly reduced via regular monitoring by the veterinarian. Indeed, once the problem had been identified and a suitable management plan to withdraw treatment was implemented, only one further case was reported (corresponding to 1.6% of dogs treated under these study conditions). This plan primarily involves bi-weekly surveillance of albumin and proteinuria during the first 3 months of treatment followed by at least monthly monitoring; recommendations based upon reports that this effect occurred almost uniquely during the first 3 months of treatment with dogs recovering quickly and without relapse after discontinuation of treatment. In this manner, discontinuation of treatment occurs while the dog is still clinically asymptomatic. Upon resolution, treatment may be resumed at a reduced dose for at least 3 months and monitored for signs of reoccurrence.

MASITINIB FOR VETERINARY ONCOLOGY

Although masitinib has been approved for the treatment of MCT in Europe for over 2 years (trade name Masive®) and has been selectively available in the US under a personal importation program for veterinarians since June 2009, it has only recently received conditional FDA approval. Marketed under the trade name Kinavet CA-1®, this TKI is now be openly available to US veterinarians for treatment of recurrent (post-surgery) or non-resectable grade II/III cutaneous mast cell tumors in dogs that have...
not previously received radiotherapy and/or chemotherapy except corticosteroids. Registration of masitinib was based upon the successful outcome of a phase III randomized clinical trial including 202 dogs with grade II/III cutaneous MCTs, recruited from 25 veterinary centers in the USA and France. This study reported that masitinib significantly delayed time-to-progression (TTP), i.e. an increased overall median TTP compared to placebo, with the effect being more pronounced when used as first-line therapy and regardless of whether the tumors expressed mutant or wild-type KIT. To further assess the long-term impact of masitinib on the survival of dogs with MCT, those dogs benefiting from treatment on the phase III study were enrolled into a compassionate-use program. Findings from the follow-up study revealed that masitinib significantly increased survival rates at 12 and 24 months in dogs with non-resectable tumors, again regardless of the MCT’s KIT mutation status. Indeed, a number of case studies from dogs that have remained on this follow-up study for almost 5 years support the claim that masitinib can represent a curative therapy for a proportion of dogs. Finally, analyses revealed that control of disease was highly correlated with long-term survival; indicating that tumor stabilization also provides important clinical benefits. This effectively introduces a new paradigm in veterinary oncology, with control of disease at 6 months being highly predictive of long-term survival, whereas short-term response at 6 weeks was not. Disease control over 6 months is therefore a valuable treatment objective when using TKIs such as masitinib, suggesting that in the absence of severe toxicity this should be the recommended duration of treatment.

The off-label use of masitinib in Europe, applicable under the Cascade provisions, has revealed some interesting case studies that are now the focus of further clinical development. These include several examples of masitinib being used for maintenance chemotherapy of dogs with T-cell multicentric lymphoma. For some of these dogs, masitinib monotherapy of T-cell lymphoma was sufficient to maintain a complete or clinical remission. These clinical observations are supported by in vitro data showing that canine T-cell lymphoma cell lines are particularly sensitive to masitinib, possibly due to inhibition of PDGFR. In another case, a dog was diagnosed as having histologically confirmed neurofibrosarcoma with mast cell infiltration. A strong relationship exists between the pathogenesis of neurofibrosarcoma and both mast cells and Schwann cells, suggesting therefore, possible benefits from treatment with targeted KIT or PDGFR inhibitors, respectively. Upon commencement of masitinib monotherapy an observed rapid tumor growth was quickly stabilized followed by a significant decrease in volume and a negligible mass after 10 weeks of treatment. There are also several reports of masitinib treatment of canine metastatic melanoma producing improved survival times compared to surgery. In one case study, the dog presented with a histologically proven metastatic melanoma that was unresponsive to chemotherapy; however, after the introduction of masitinib a complete response was achieved within 2 months of treatment. This dog was alive at least 4 months after the initial resection, before being lost to follow-up. These observations suggest that masitinib might represent a therapeutic option for dogs with melanoma; a hypothesis again supported by in vitro findings. In feline case studies, one subject with MCT experienced rapid improvement in clinical status after 7 days of masitinib treatment and partial response in two sub-cutaneous nodules. Another feline subject presenting with metastasized cutaneous melanoma, for which the primary tumor had been resected, showed a complete response after 6 months of daily masitinib treatment with no signs of relapse following 14 months of treatment. Finally, an in vitro study on feline vaccine associated sarcomas cell lines showed masitinib had potential as an antineoplastic agent against this disease.

There is evidence that masitinib can act as a potentiator of chemotherapies. For example, it was shown to strongly sensitize histiocytic sarcoma cells to vinblastine; osteosarcoma and mammary carcinoma cells to gemcitabine; and to a lesser degree, several cell lines were sensitized to doxorubicin. Phase I
studies in dogs with advanced tumors have shown that masitinib in combination with carboplatin or doxorubicin had acceptable and manageable safety profiles, without added toxicity. Furthermore, studies show that masitinib can enhance the antiproliferative effects of gemcitabine in human pancreatic cancer, a property not seen with other TKIs such as imatinib and dasatinib. The working hypothesis is that an as yet unidentified protein or signaling pathway important in the restoration of chemotherapy response is being affected; research is on-going.

MASITINIB FOR IMMUNE-MEDIATED DISEASES

Studies also support the potential use of TKIs in non-oncological disorders. As previously mentioned, the main cellular target of masitinib are mast cells, which are capable of releasing large amounts of pro-inflammatory mediators with a consequence of triggering and sustaining an inflammatory response. Masitinib can therefore also provide therapeutic benefit in immune-mediated diseases with mast cell involvement, such as atopic dermatitis, asthma, inflammatory bowel disease and arthritis. The most advanced of these applications is canine atopic dermatitis, for which a phase III study incorporating one of the largest cohorts tested to date, showed a significant reduction of clinical signs following masitinib treatment. Findings from this study have recently been published in the journal *Veterinary Dermatology*. Briefly, a positive response was evident for treatment-naïve dogs, dogs resistant to ciclosporin and/or corticosteroids, and dogs with severe pruritus, the latter two groups representing populations with high unmet medical need. More specifically, a reduction in CADESI-02 score of $\geq 50\%$ at week 12 was observed in 61% of masitinib-treated dogs vs. 35% control; according to the intent-to-treat population, observed cases dataset. For dogs resistant to ciclosporin and/or corticosteroids, this response rate was 60% vs. 31% control. Overall, 63% of investigators assessed masitinib efficacy as good/excellent vs. 35% control.

Feline asthma is another disorder that may benefit from TKI therapy. To date, a few encouraging case studies support this; one cat presenting with corticosteroid-intolerance and another with corticosteroid-resistance, for which both have been treated with masitinib for over 14 months and show an improved quality-of-life. Such reports prompted further clinical study including a randomized, controlled phase II study of oral masitinib (50 mg/day) for treatment of experimental feline asthma, which produced positive responses including a significant reduction in bronchiolar resistance and eosinophilic airway inflammation after 4 weeks.

CONCLUSIONS

Proven beyond doubt as a successful long-term anti-cancer treatment for MCT, masitinib also shows real promise as a valuable treatment option in canine atopic dermatitis, especially for those dogs that are severely pruritic or refractory to current therapies. The application of TKIs in the veterinary setting, and even more so their specific development to address unmet medical needs related to veterinary medicine, is still considered somewhat of a novelty. However, with an expanded range of indications for which TKIs feature routinely as a viable therapeutic option along with further acquisition of long-term data demonstrating clear therapeutic benefits from their use, then TKIs may soon become established as the veterinarian’s benchmark treatment for certain diseases.
3.1 PUBLICATIONS NEW TO THIS ISSUE

- Publication of the full phase 3 canine atopic dermatitis study findings in the journal of Veterinary Dermatology. Manuscript title: ‘Masitinib decreases signs of canine atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial’.

- Publication of a review article in the journal CAB Reviews and VetMed Resources website covering the clinical development of masitinib in veterinary medicine to date, discussion of safety-related issues, and emerging new therapeutic directions. Manuscript title: ‘Masitinib – a targeted therapy with applications in veterinary oncology and inflammatory diseases’.


3.2 FUTURE PUBLICATIONS AND CONGRESS PRESENTATIONS

- Publication of findings from a study on feline vaccine associated sarcoma. Manuscript provisionally entitled: ‘Masitinib demonstrates antiproliferative and proapoptotic activity in primary and metastatic feline vaccine associated sarcoma cells’ is currently under journal review.

- Publication of full research findings from the feline asthma study. Manuscript provisionally entitled: ‘The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma’ is currently under journal review.

- Publication of full research findings from two phase 1 studies to determine the maximum tolerated dose of the chemotherapies carboplatin or doxorubicin in combination with masitinib, and to evaluate the safety and efficacy of these combination therapies in dogs with advanced tumours. Manuscript provisionally entitled: ‘Masitinib in combination with carboplatin or doxorubicin in advanced canine tumours’ is currently under journal review. Results include positive treatment response in three dogs with anal carcinoma.

3.3 RECENT NEWSWORTHY EVENTS – AB SCIENCE PRESS RELEASES

Paris, June 26th 2011, 5:30 pm

CAB Reviews and VetMed Resources publish a comprehensive review on the clinical development of masitinib in veterinary medicine

AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of a wide-ranging review article entitled ‘Masitinib – a targeted therapy with applications in veterinary oncology and inflammatory diseases,’ in the peer-reviewed journal CAB Reviews and on the veterinary continuing education website VetMed Resources (the most comprehensive online veterinary information service).

Professor Barbara E. Kitchell (DMV, PhD, DACVIM; Michigan State University, USA) declared: «Perhaps the most compelling aspect of masitinib from a veterinarian’s viewpoint is the possible diversity of its applications. Already documented to be a valuable anticancer therapeutic for mast cell tumor treatment of dogs, masitinib also shows real promise as effective treatment of canine atopic dermatitis. Considering also the wide range of other cancer and anti-inflammatory treatments currently being explored by veterinary investigators, masitinib seems likely to become an increasingly important tool in the veterinarian’s therapeutic armamentarium. »

 Authored by leading experts in the fields of veterinary oncology, veterinary dermatology, and tyrosine kinase inhibitor research, this article reviews the clinical development of masitinib in veterinary medicine to date, discussing key results from its canine mast cell tumor and atopic dermatitis phase 3 studies, safety-related issues, and emerging new therapeutic directions.

Commenting on the significance of masitinib to the veterinary community, Robert Taylor, editor of CABI’s VetMed Resource, stated that: « We invited this review on masitinib and its use in dogs, because of the current interest within the veterinary profession on this new class of anti-neoplastic agents and the promise they have in treating common cancers such as mast cell tumors. Veterinarians are increasingly interested in reviewing the published literature so that they can base their practice on the best available evidence. »

Professor Olivier Hermine, President of the scientific committee of AB Science commented: «This paper makes extensive use of source material from investigators in the field who are sharing their experiences of masitinib treatment with the scientific community. The importance of such communications cannot be underestimated as they help identify new therapeutic opportunities and we therefore welcome dialogue with investigators planning to initiate studies. Due to the broad therapeutic possibilities of masitinib such interactions may even be essential if we wish to maximize this drug’s benefits in human medicine – experiences and insights from the veterinary setting often serving as a catalyst for further clinical development that can result in tangible benefits for human health. We have already seen an example of such cross-fertilization with the initiation of AB Science’s phase 3 study in human metastatic melanoma. »

This publication is available from the online library of either VetMed Resources or CAB Reviews (www.cabi.org/vetmedresource) (www.cabi.org/cabreviews) and can be cited as: Ogilvie GK et al. CAB Reviews: Perspectives in Agriculture, Veterinary Science, Nutrition and Natural Resources, 2011, 6, No. 021, doi: 10.1079/PAVSNNR20110021. A pre-publication author version is also available to download from the following weblink: [DOWNLOAD HERE](https://docs.google.com/viewer?a=v&pid=explorer&chrome=true&srcid=0B4Of9Adqv406YzA5Y2FmNWEtYjU1Ny00MGVlLThhZjQtNDQ2MjY3NDkxNTI4&hl=en_US)

(Full press release available online or upon request to AB Science - contact@ab-science.com)
**Masitinib decreases signs of canine atopic dermatitis**

**Publication of phase 3 results in Veterinary Dermatology**

**AB Science SA** (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of results from its phase 3 clinical trial investigating the treatment of canine atopic dermatitis with masitinib in *Veterinary Dermatology*, the lead journal in this field of research. The article entitled, ‘Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial’, shows that masitinib has potential as an effective treatment of canine atopic dermatitis. Important facts about this study include:

- Pivotal phase 3 study with one of the largest atopic dermatitis cohorts tested to date, 306 dogs, and a highly robust study design
- Masitinib achieved statistically significant reduction in the signs of canine atopic dermatitis
- Positive response to masitinib was evident for dogs resistant or intolerant to ciclosporin and/or corticosteroids, and dogs with severe pruritus; two populations with high unmet medical need
- Masitinib could provide an important new tool in the veterinarian’s armamentarium for effective treatment of canine atopic dermatitis

The treatment of generalized canine atopic dermatitis remains a challenge, especially in severe or refractory cases. Beyond the already developed therapeutic strategies, there exists an unmet medical need to identify alternative treatments. Mast cells are known to produce a variety of inflammatory mediators that are in part responsible for the complex inflammatory cascade associated with allergic disease. As such, mast cells represent an attractive, hitherto untapped, therapeutic target for atopic dermatitis management. Masitinib, a selective oral tyrosine kinase inhibitor, effectively inhibits the survival, migration and activity of mast cells.

Dr. Pierre Cadot (Dr.med.vet., Clinique vétérinaire Europa, France) the article’s lead author declared: “The key message from this study has to be that daily administration of oral masitinib achieved significant reduction in the signs of canine atopic dermatitis and could therefore be an effective treatment option. This positive response was evident not only in dogs that had never received treatment before but also in dogs resistant or intolerant to ciclosporin or corticosteroids, and dogs with severe pruritus, two groups representing populations with high unmet medical need”.

Dr. Patrick Hensel (Dr.med.vet., DACVD, University of Georgia, USA) the study’s coordinating investigator commented: “This study was up to date one of the largest randomized, controlled clinical drug trials in the treatment of canine atopic dermatitis. Animals were carefully selected to meet the required criteria of atopic dermatitis. The findings of this study indicate that masitinib, which is selectively targeting mast cells, decreased clinical signs in the study population”.


(Full press release available online or upon request to AB Science - contact@ab-science.com).
AB Science announces presentation at the 2011 ACVIM Forum of two invited talks on veterinary use of masitinib

AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces that two invited presentations on the topic of veterinary applications of masitinib will be delivered by Dr Albert Ahn at the American College of Veterinary Internal Medicine (ACVIM) Forum to be held in Denver, USA next month (www.acvim.org/websites/forum2011). Full length manuscripts for both of these presentations will be published in the 2011 ACVIM Forum Proceedings.

Dr Albert Ahn (DVM, President of AB Science USA) commented: «Since masitinib received conditional approval for treatment in canine mast cell tumor from the US Food and Drug Administration (FDA) in December 2010, as well as the recent publication of impressive long term survival data in that disease and completion of a successful pivotal trial for treatment of canine atopic dermatitis, there has been a real demand from the veterinary community for more information about this remarkably versatile drug. These invited presentations and their accompanying manuscripts go some way to quench that thirst.»

As part of this initiative on information transfer, AB Science has also created an information pack of masitinib-related veterinary publications titled ‘Masitinib Scientific Data for Veterinary Medicine’, intended to provide a convenient one-stop reference source, covering peer-reviewed journal articles, meeting abstracts, conference proceeding manuscripts, press articles, and press-releases communicated by international news agencies. The next edition is scheduled for release in July and is available upon request from contact@ab-science.com.

The first 2011 ACVIM Forum talk, entitled ‘Masitinib in Canine Mast Cell Disease’, will be part of the Oncology - Specialty Symposium (Wednesday 15th June at 2:45 pm). Masitinib was specifically designed to target mast cells, working therefore directly at the origin of the tumor, in contradistinction to standard cytotoxic chemotherapies that inhibit replication of all cells, including healthy and useful ones. This talk will review data from the successful pivotal trial that evaluated 202 dogs with grade II/III cutaneous mast cell tumor, long term findings at 12 and 24 months from the follow-up study, and case studies exemplifying survival of over 4.5 years in dogs from the pivotal trial’s extension phase. The manuscript accompanying this talk will be published as part of the 2011 ACVIM Forum Proceedings and can also be downloaded from the following link: 2011 ACVIM Forum - Masitinib in Canine Mast Cell Disease

The second 2011 ACVIM Forum talk is part of the Technician Program, in which Dr Albert Ahn presents a comprehensive review on the emerging role of tyrosine kinase inhibitors in veterinary medicine and in particular masitinib. Topics will range from findings of the two completed phase III studies in canine oncology and immune-mediate indications, as well as the development program for numerous other canine and feline oncology and non-oncological diseases. The talk is entitled ‘New Therapeutic Options in Veterinary Oncology: Tyrosine Kinase Inhibitors’, and is scheduled for Saturday 18th June at 5:25 pm. The manuscript accompanying this talk will be published as part of the 2011 ACVIM Forum Proceedings and can also be downloaded from the following link: 2011 ACVIM Forum - Masitinib Scientific Data for Veterinary Medicine

(Full press release available online or upon request to AB Science - contact@ab-science.com)
Veterinary Dermatology to publish findings from AB Science’s successful phase 3, controlled clinical trial of masitinib in the treatment of canine atopic dermatitis

AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces official acceptance from the journal Veterinary Dermatology to publish findings from its phase 3 clinical trial of masitinib in the treatment of canine atopic dermatitis. Veterinary Dermatology, the leading journal in this field of research, will publish the paper entitled ‘Masitinib decreases signs of canine atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial’ in the coming weeks.

This was a 12-week, prospective, multicentre, randomized, double-blind, placebo-controlled, pivotal phase 3 study to compare efficacy and safety of masitinib at 12.5 mg/kg/day to a control, in the treatment of canine atopic dermatitis. Atopic dermatitis is a chronic, pruritic inflammatory skin disease. Its severity can range from an annoyance in the form of mild itching through to debilitating extensive lesion coverage that has a profoundly negative impact on the quality-of-life. Beyond the already developed therapeutic strategies, there exists an unmet medical need to identify alternative treatments for canine atopic dermatitis that can demonstrate high efficacy over time in monotherapy, exploit novel therapeutic targets for more effective combination therapies or treatment of dogs resistant to current therapies, and minimize long-term toxicity.

Professor Olivier Hermine, President of the scientific committee of AB Science commented: «Canine atopic dermatitis is the first non-oncological veterinary application for masitinib, although this is certainly not a case of a chemotherapeutic agent being applied outside of its ‘designated’ field of use. In fact, it is a common misnomer to describe masitinib as a chemotherapeutic agent because unlike cytotoxic chemotherapies that inhibit replication of all cells, including healthy cells, masitinib is a targeted therapy. Moreover, depending on which kinases are targeted, tyrosine kinase inhibitors such as masitinib are equally well-suited for the treatment of non-oncology diseases, as has been demonstrated by numerous human clinical trials with masitinib ».

The findings presented in this publication proved masitinib to be an effective and mostly well tolerated treatment for canine atopic dermatitis. A positive response to masitinib was evident for treatment-naïve dogs, dogs resistant to ciclosporin and/or corticosteroids, and dogs with severe pruritus, the latter two groups representing populations with high unmet medical need. It was concluded therefore, that masitinib could provide an important new tool in the veterinarian’s armamentarium for effective treatment of canine atopic dermatitis.

Alain Moussy, Chairman and CEO of AB Science declared: «This publication represents an important milestone in the masitinib veterinary development program in the treatment of canine atopic dermatitis, in so much as it adds a stamp of approval from the relevant scientific community. Veterinary Dermatology is the leading journal in the field, for which the peer-review process is correspondingly rigorous. »

This article will soon be available electronically from Veterinary Dermatology’s website. Publication in the paper version scheduled for the coming months.

(Full press release available online or upon request to AB Science - contact@ab-science.com).
Publication of preclinical results demonstrates that masitinib can act as a potentiator of chemotherapies

AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces publication in The Veterinary Journal of results from a preclinical study showing that masitinib has potential as a chemosensitizer.

This study, conducted by Dr Douglas Thamm (VMD, Diplomate ACVIM Oncology; Colorado State University) and colleagues, investigated the ability of masitinib to sensitize different canine cancer cell lines to various chemotherapeutic agents. Results showed that masitinib sensitized numerous tumor cell lines from different origins (breast, bladder, melanoma, lymphoma, etc.) to chemotherapeutic drugs such as doxorubicin, gemcitabine and vinblastine. These data also provide additional weight to findings from studies showing that masitinib can enhance the antiproliferative effects of gemcitabine in human pancreatic cancer, including gemcitabine-resistant cell lines, which is a property not seen with other tyrosine kinase inhibitors (Humbert et al. PLoS One, 2010).

Dr Douglas Thamm declared: « This study provides further evidence that masitinib can exert an anticancer action that extends beyond the inhibition of its main tyrosine kinase targets by acting in synergy with standard chemotherapies. Such chemosensitization may allow lower concentrations of chemotherapeutic agent to be used, thereby reducing toxicity risks, or may increase the available efficacy at standard doses ».

Professor Olivier Hermine, President of the scientific committee of AB Science commented: « These data taken together with findings in human pancreatic cancer cell lines are highly significant because one of the main limitations to certain chemotherapy treatments is drug resistance, and so a drug capable of counteracting resistance would facilitate the prolonged therapeutic benefits of such chemotherapies ».


To read more about publications of masitinib in human and veterinary medicine visit www.ab-science.com

(Full press release available online or upon request to AB Science - contact@ab-science.com).
Publication of Long-Term Survival of Dogs with Mast Cell Tumours Treated with Masitinib

AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), announces publication of increased long-term survival with masitinib in canine mast cell tumour.

In new research published in the peer-reviewed scientific journal American Journal of Veterinary Research, Dr Kevin Hahn (DVM, PhD) and colleagues report on the effectiveness of masitinib for the treatment of nonresectable mast cell tumours (MCTs) in dogs at 12 and 24 months after onset of treatment. This was a follow-up study from the successful pivotal 6-month, phase III, placebo-controlled clinical trial of masitinib in the treatment of dogs with nonmetastatic grade 2 or grade 3 cutaneous MCTs. Masitinib, arguably the most specific inhibitor of c-Kit available, was subsequently registered by the European Medicine Agency (EMA) under the trade name Masivet®, making it the first approved targeted therapy in veterinary oncology. Masitinib recently received conditional approval from the Food and Drug Administration (FDA) for commercialisation under the trade name Kinavet-CA1.

Two major conclusions are drawn from this publication. First, the long-term follow-up data provides further evidence that masitinib is effective in the treatment of nonresectable MCTs and provided benefits in terms of long-term survival. Moreover, masitinib treatment was shown to improve long-term survival regardless of the subtype of MCT being treated (with respect to c-Kit mutational status). Second, analysis revealed that control of disease at 6 months was highly predictive of long-term survival, whereas short-term response at 6 weeks was not.

Alain Moussy, Chairman and CEO of AB Science declared: « In the field of oncology this survival is critically important to establish a drug as a benchmark. Recent examples have shown that oncology products could reduce tumour size in the short-term at a cost of toxicity but could not increase survival over the long-term or even worse reduce survival. It is relatively difficult to generate these long-term survival data because you need to follow patients in a comparative manner (that is, masitinib versus existing standard of care) for years, which AB Science has done. Significant improved survival has been demonstrated, which is good news for dogs suffering from mast cell tumours ».

Publication is available from the AJVR website:

(Full press release available online or upon request to AB Science - contact@ab-science.com).
4.1 MASITINIB (AB1010), A POTENT AND SELECTIVE TYROSINE KINASE INHIBITOR TARGETING KIT

Publication Category: Peer Reviewed Journal (Full manuscript available in appendices or upon request to AB Science - contact@ab-science.com)


BACKGROUND: The stem cell factor receptor, KIT, is a target for the treatment of cancer, mastocytosis, and inflammatory diseases. Here, we characterise the in vitro and in vivo profiles of masitinib (AB1010), a novel phenylaminothiazole-type tyrosine kinase inhibitor that targets KIT.

METHODOLOGY/PRINCIPAL FINDINGS: In vitro, masitinib had greater activity and selectivity against KIT than imatinib, inhibiting recombinant human wild-type KIT with an half inhibitory concentration (IC(50)) of 200+/−40 nM and blocking stem cell factor-induced proliferation and KIT tyrosine phosphorylation with an IC(50) of 150+/−80 nM in Ba/F3 cells expressing human or mouse wild-type KIT. Masitinib also potently inhibited recombinant PDGFR and the intracellular kinase Lyn, and to a lesser extent, fibroblast growth factor receptor 3. In contrast, masitinib demonstrated weak inhibition of ABL and c-Fms and was inactive against a variety of other tyrosine and serine/threonine kinases. This highly selective nature of masitinib suggests that it will exhibit a better safety profile than other tyrosine kinase inhibitors; indeed, masitinib-induced cardiotoxicity or genotoxicity has not been observed in animal studies. Molecular modelling and kinetic analysis suggest a different mode of binding than imatinib, and masitinib more strongly inhibited degranulation, cytokine production, and bone marrow mast cell migration than imatinib. Furthermore, masitinib potently inhibited human and murine KIT with activating mutations in the juxtamembrane domain. In vivo, masitinib blocked tumour growth in mice with subcutaneous grafts of Ba/F3 cells expressing a juxtamembrane KIT mutant.

CONCLUSIONS: Masitinib is a potent and selective tyrosine kinase inhibitor targeting KIT that is active, orally bioavailable in vivo, and has low toxicity.
4.2 MASITINIB AS A CHEMOSENSITIZER OF CANINE TUMOR CELL LINES

Publication Category: Peer Reviewed Journal (Full manuscript available in appendices or upon request to AB Science - contact@ab-science.com)


SUMMARY
Masitinib, a selective tyrosine kinase inhibitor, has previously been shown to enhance the antiproliferative effects of gemcitabine in human pancreatic cancer, demonstrating potential as a chemosensitizer. This exploratory study investigated the ability of masitinib to sensitize various canine cancer cell lines to doxorubicin, vinblastine, and gemcitabine. Masitinib strongly sensitized histiocytic sarcoma cells to vinblastine (>70-fold reduction in IC_{50} at 5 µM masitinib), as well as osteosarcoma and mammary carcinoma cells to gemcitabine (>70-fold reduction at 5–10 µM). In addition, several cell lines were sensitized to doxorubicin (2–10-fold reduction at ≤ 10 µM). These data establish proof-of-concept that masitinib in combination with chemotherapeutic agents can generate synergistic growth inhibition in various canine cancers, possibly through chemosensitization. The findings justify further investigation into those combinations that may potentially yield therapeutic benefit.

4.3 GAIN-OF-FUNCTION MUTATIONS IN THE EXTRACELLULAR DOMAIN OF KIT ARE COMMON IN CANINE MAST CELL TUMORS

Publication Category: Peer Reviewed Journal (Full manuscript available in appendices or upon request to AB Science - contact@ab-science.com)


SUMMARY:
In the current study, we examined the types and frequency of KIT mutations in mast cell tumors from 191 dogs. Sequencing of reverse transcription-PCR products revealed alterations in 50 (26.2%) of the dogs. Most mutations were in exon 11 (n = 32), and of these, most were internal tandem duplications (n = 25) between residues 571 and 590. Within exon 11, there were two hotspots for mutations at codons 555-559 and 571-590. In addition, nine dogs had mutations in exon 8 and eight had mutations in exon 9. We selected the two most common mutants and two representative exon 11 mutants for further analysis. When expressed in Ba/F3 cells, they were constitutively tyrosine phosphorylated and induced growth factor-independent cell proliferation. AG1296, a tyrosine kinase inhibitor, dose dependently inhibited both the tyrosine phosphorylation of these mutants and their induction of growth factor-independent proliferation. This study shows that activating mutations in not only exon 11 but also exons 8 and 9 are common in canine mast cell tumors. These results also show that Ba/F3 cells can be used for the direct characterization of canine KIT mutants, eliminating the need to make equivalent mutations in the mouse or human genes.
SUMMARY

Abstract: Mast cell proliferation, differentiation, and degranulation (the release of inflammatory cytokines and mediators that may have a physiological or pathological effect) is regulated by the growth factor receptor, c-Kit. Inhibitors of the c-Kit receptor may therefore have a beneficial effect in diseases conditions that involve mast cells. The objective of this work was to demonstrate the biological benefits of masitinib administration in three different in vivo rodent models of chronic inflammatory diseases.

In one model of allergic airway inflammation, Balbc mice sensitized to ovalbumine were given masitinib (25 or 100 mg/kg/day, p.o., after the sensitization process). Masitinib diminished significantly the airway hyperresponsiveness (30% reduction) during a methacholine challenge test (measured by the bronchconstrictive response) and significantly reduced the number of eosinophils in the bronchoalveola lavage fluid (70% reduction) (n.5, p<0.05).

Similarly, in another model of dextran sodium sulphate-induced colitis in Balbc mice, masitinib dose dependently (25mg/kg and 50mg/kg) significantly reduced the symptoms (10% and 50% reduction of weight loss) and extent of macroscopic and histological lesions (25% and 50%) as well as colonic concentrations of myeloperoxydase (MPO) and inflammatory cytokines including TNF alpha (n.10; p<0.05).

The results obtained from these in vivo studies in addition to our previous report regarding the beneficial symptomatic improvements noted in dogs with atopic dermatitis provide a rationale to perform studies with of c-kit inhibitors in other chronic inflammatory disorders involving mast cells in dogs including asthma and inflammatory bowel diseases.
INTRODUCTION: We recently showed that masitinib, a tyrosine kinase inhibitor targeting c-Kit, PDGF receptor and FGFR3 and affecting the FAK pathway, is safe and effective for the treatment of grade II or III nonresectable or recurrent mast cell tumors in dogs. To investigate the possible use of masitinib in combination with chemotherapy in dogs, we examined its ability to sensitize canine cancer cell lines to doxorubicin, vinblastine, and gemcitabine.

METHODS: A variety of canine tumor cells were incubated for 72 h with varying concentrations of chemotherapeutic agent +/- masitinib. Relative viable cell number was then determined using a commercial bioreductive fluorometric assay, expressed as a percentage versus untreated cells, and 50% inhibitory concentrations calculated using nonlinear regression, fitting the data to a sigmoidal dose-response curve.

RESULTS: Masitinib demonstrated potent single-agent antiproliferative activity against OSW canine T-cell lymphoma. Masitinib (1-10 µM) sensitized all evaluated cell lines to doxorubicin (2- to 10-fold reduction in IC50), strongly sensitized DH82 histiocytic sarcoma cells to vinblastine (>74-fold reduction), and strongly sensitized D17 and Abrams osteosarcoma and CMT12 and CMT27 mammary carcinoma cells to gemcitabine (>10-fold reduction).

CONCLUSIONS: Masitinib can chemosensitize canine tumor cell lines to the antiproliferative effects of multiple antineoplastic drugs at clinically achievable concentrations. The OSW canine T cell lymphoma cell line demonstrates unique sensitivity to masitinib through an s-yet unknown mechanism. The encouraging data presented here strongly justify clinical evaluation of masitinib/chemotherapy combinations in dogs with spontaneous tumors.
Summary

Since their introduction about 10 years ago, tyrosine kinase inhibitors (TKI) have revolutionized the treatment of certain diseases in human medicine and represent a cutting-edge technology in cancer therapeutics. Today, armed with positive findings from two phase III randomized controlled trials, including approximately 6 years long-term follow-up data in canine mast cell tumor, 2 years of European post-market experience, and recently acquired regulatory approval from the US Food and Drug Administration (FDA), the TKI known as masitinib is set to do likewise for veterinary medicine. Drugs of this class inhibit protein tyrosine kinases, enzymes involved in cellular signaling pathways that regulate key cell functions such as proliferation, differentiation, migration, activation and survival. Activation of these enzymes, through mechanisms such as point mutations or over expression, can lead to various forms of cancer as well as non-oncological disorders. The first oncological disorder targeted by this drug has been canine mast cell tumors (MCT). This cancer is the most common cutaneous malignant neoplasm in dogs. However, masitinib has therapeutic potential beyond the field of chemotherapeutics, its highly targeted mechanism of action generating treatment possibilities in a large number of immune-mediated and neurological conditions. This diversity is exemplified via a successful phase III study that showed significant reduction in the symptoms of canine atopic dermatitis following treatment with masitinib.
5.2 EVALUATION OF 12- AND 24-MONTH SURVIVAL RATES AFTER TREATMENT WITH MASITINIB IN DOGS WITH NONRESECTABLE MAST CELL TUMORS

Publication Category: Peer Reviewed Journal (Full manuscript available in appendices or upon request to AB Science - contact@ab-science.com)


Erratum in:

OBJECTIVE: To evaluate the effectiveness of masitinib for the treatment of nonresectable mast cell tumors (MCTs) in dogs at 12 and 24 months after onset of treatment.

ANIMALS: 132 dogs with nonresectable grade 2 or 3 MCTs.

PROCEDURES: Dogs received masitinib (12.5 mg/kg/d, PO; n = 106) or a placebo (26). After 6 months, treatment was extended with tumor assessments at 3-month intervals until detection of disease progression. Endpoints were tumor response and overall survival rate and time.

RESULTS: In dogs with nonresectable MCTs, masitinib significantly improved survival rate, compared with results for the placebo, with 59 of 95 (62.1%) and 9 of 25 (36.0%) dogs alive at 12 months and 33 of 83 (39.8%) and 3 of 20 (15.0%) dogs alive at 24 months, respectively. Median overall survival time was 617 and 322 days, respectively. Tumor control at 6 months had a high predictive value for 24-month survival, with high specificity (88%) and sensitivity (76%), whereas short-term tumor response (within 6 weeks) had a poor predictive value. Complete responses at 24 months were observed in 6 of 67 (9.0%) dogs with nonresectable MCTs treated with masitinib.

CONCLUSIONS AND CLINICAL RELEVANCE: Masitinib significantly increased survival rates at 12 and 24 months in dogs with nonresectable MCTs. Control of disease at 6 months, but not best response at 6 weeks, was predictive of long-term survival in dogs treated with masitinib, which suggested that short-term response may be irrelevant for assessing clinical efficacy of tyrosine kinase inhibitors for treatment of MCTs.
5.3 MASITINIB IS SAFE AND EFFECTIVE FOR THE TREATMENT OF CANINE MAST CELL TUMORS

Publication Category: Peer Reviewed Journal (Full manuscript available in appendices or upon request to AB Science - contact@ab-science.com)


BACKGROUND: Activation of the KIT receptor tyrosine kinase is associated with the development of canine mast cell tumors (MCT).

HYPOTHESIS/OBJECTIVE: To evaluate the efficacy of masitinib, a potent and selective inhibitor of KIT, in the treatment of canine MCT.

ANIMALS: Two hundred and two client-owned dogs with nonmetastatic recurrent or nonresectable grade II or III MCT.

METHODS: Double-blind, randomized, placebo-controlled phase III clinical trial. Dogs were administered masitinib (12.5 mg/kg/d PO) or a placebo. Time-to-tumor progression (TTP), overall survival, objective response at 6 months, and toxicity were assessed.

RESULTS: Masitinib increased overall TTP compared with placebo from 75 to 118 days (P = 0.038). This effect was more pronounced when masitinib was used as first-line therapy, with an increase in the median TTP from 75 to 253 days (P = 0.001) and regardless of whether the tumors expressed mutant (83 versus not reached [P = 0.009]) or wild-type KIT (66 versus 253 [P = 0.008]). Masitinib was generally well tolerated, with mild (grade I) or moderate (grade II) diarrhea or vomiting as the most common adverse events.

CONCLUSIONS AND CLINICAL IMPORTANCE: Masitinib is safe and effective at delaying tumor progression in dogs presenting with recurrent or nonresectable grade II or III nonmetastatic MCT.
5.4 FIFTY MONTHS AND COUNTING: CASE STUDIES EXEMPLIFYING THE LONG-TERM SURVIVAL OF MASITINIB IN DOGS WITH NON-RESECTABLE GRADE II MAST CELL TUMORS

Publication Category: Conference Presentation

Proceedings of the 30th Annual Conference of the Veterinary Cancer Society, October 29-November 1, 2010
(also in Veterinary and Comparative Oncology, 9, 1, e1–e49. DOI: 10.1111/j.1476-5829.2010.00252.x)
Phillips B, Legendre A, Shaw N, Ahn A

INTRODUCTION: In general, the objective of anti-cancer treatment is tumor control leading to prolonged survival and ideally a complete response.

METHODS: Presented are case studies that exemplify the long-term survival, even curative, benefits of masitinib, a tyrosine kinase inhibitor that potently and selectively targets c-Kit and consequently mast cells, in dogs with non-resectable grade II mast cell tumors (MCT).

RESULTS: Each dog has received oral masitinib in monotherapy for over 4 years as part of a pivotal trial’s extension phase. Key results from that study included a decrease in tumor size by ≥50% during the first 6 months in 50% of masitinib-treated dogs, versus 29% in the placebo group (p=0.02). Moreover, follow-up data at 24 months reported six masitinib-treated dogs (9%) maintained complete tumor response compared to none with placebo. Sustainability of this long-term response is further evidenced from the three dogs that remain in the extension phase. The first and second cases presented as non-resectable grade II MCT with c-Kit mutation (exon 11 and exon 8, respectively). Complete response was achieved with masitinib as first-line treatment, which has persisted for approximately 57 months and 52 months, respectively. The third case presented with non-resectable grade II MCT and no c-Kit mutation (wild-type). Masitinib administered as a third-line treatment induced a complete response, lasting now for approximately 53 months. Masitinib has been well tolerated over this time, as evident by the clinical report files.

CONCLUSION: Masitinib significantly improves long-term survival of dogs with non-resectable tumors, irrespective of the presence of c-Kit mutations.
5.5 FIRST-LINE AND RESCUE THERAPY WITH MASITINIB INTEGRATED PROTOCOLS FOR CANINE CUTANEOUS MAST CELL TUMORS.

Publication Category: Conference Presentation

Proceedings of the 30th Annual Conference of the Veterinary Cancer Society, October 29-November 1, 2010
(also in Veterinary and Comparative Oncology, 9, 1, e1–e49. DOI: 10.1111/j.1476-5829.2010.00252.x)
Johan de Vos and Malcolm Brearley

INTRODUCTION: How tyrosine kinase inhibitors will be integrated into standard chemotherapy protocols for canine mast cell tumors (MCT) has yet to be determined. This study investigates masitinib incorporation in first-line and rescue therapy of canine cutaneous MCTs.

METHODS: 44 dogs with incompletely removed or non-resectable cutaneous MCT received masitinib in a variety of settings. Group A: masitinib only (n=11: 2 gr-II, 4 gr-III, 5 gr-unknown). Group B: masitinib/prednisone (n=13: 1 gr-I c-KIT mutated, 3 gr-II, 5 gr-III, 4 gr-unknown). Group C: masitinib/prednisone, plus vinblastine and/or lomustine (n=11: 6 gr-II, 5 gr-III). Group D chemoresistant masitinib rescue (n=9: 1 gr-II, 5 gr-III, 3 gr-unknown). Survival analyses were performed by Kaplan Meier Product limit method.

RESULTS: 27 dogs achieved CR, 6 PR, 5 SD, and 6 PD. c-KIT status was known in 9 MCTs: 7 mutated all achieved CR, 2 wild-type had SD. There were 17 tumor-related and 2 treatment-related deaths, 5 died from unrelated causes. Twenty dogs remain alive (51-539 days; 4 off treatment). The MSTs for the treatment groups were: A-136 days (4 CR; 3/11 alive); B-not reached (10 CR; 10/13 alive); C-273 days (8 CR; 5/11 alive); D-87 days (5 CR; 2/9 alive for 281 and 334 days). The MST for cases achieving CR was significantly longer than those that did not (NR vs. 81 days; p=0.0001), irrespective of grade or group.

CONCLUSIONS: Completeness of remission, not grade or protocol, was the most significant prognostic factor for MST following masitinib integrated protocols for canine naïve and drug-resistant MCTs.
5.6 IMPACT OF MASITINIB ON METASTATIC MAST CELL TUMORS AND ON THE EMERGENCE OF METASTASIS FROM NON-METASTATIC TUMORS

Publication Category: Conference Presentation

Proceedings of the 29th Annual Conference of the Veterinary Cancer Society, October 16-19, 2009
Olivier Hermine

INTRODUCTION: Masitinib is a tyrosine kinase inhibitor targeting c-Kit, the growth factor receptor of mast cells (MCs). Masitinib targets both mutated forms of c-Kit found in tumoral MCs and wild type c-Kit in normal MCs. Normal MCs may facilitate the invasion of tumoral cells in surrounding tissues via the release of proteases loosening tissues and angiogenic factors favoring tumor neovascularization, one of the steps leading to metastasis. Therefore, masitinib not only targets tumoral MCs, but may also exhibit antimetastatic properties by inhibiting normal MCs. This hypothesis is supported by several observations from clinical trials with masitinib.

METHODS: During the pivotal clinical field study, masitinib (12.5 mg/kg/day) significantly reduced the emergence of nodal/visceral metastases in dogs with recurrent or nonresectable grade 2/3 cutaneous MCT without lymph node or visceral metastases. Only 3.7% of dogs receiving masitinib developed nodal or visceral metastases (versus 17.1% of dogs under placebo; p<0.001).

RESULTS: During a pilot study, masitinib (9.2-12.5 mg/kg/day) induced long-lasting complete remission in two out of three dogs presenting with nodal and/or visceral metastases, including one dog in first-line of treatment and one dog that had received cytotoxic chemotherapy. The dog that showed progression had prior surgical resection and several cycles of cytotoxic chemotherapy. Accordingly, post-marketing experience reported that masitinib (10-12.5 mg/kg/day) induced complete responses in three out of five dogs presenting with metastasized and chemotherapy-resistant MCTs.

CONCLUSIONS: Overall, these data suggest that masitinib exhibits anti-metastatic properties by preventing the emergence of nodal/visceral metastases in non-metastatic tumor and inducing complete remissions of metastatic MCTs.
MASITINIB IN THE TREATMENT CANINE GRADE 2/3 MAST CELL TUMORS THAT ONLY EXPRESS WT C-KIT

Publication Category: Conference Presentation

Proceedings of the 29th Annual Conference of the Veterinary Cancer Society, October 16-19, 2009
Olivier Hermine

INTRODUCTION: Masitinib is a tyrosine kinase inhibitor targeting c-Kit, the growth factor receptor of mast cells. Masitinib inhibits both constitutively active mutated forms of c-Kit (found in 25% of mast cell tumors, MCTs) and wild type (WT) c-Kit.

METHODS: The efficacy of masitinib in MCTs was tested in a multicenter, randomized, placebo-controlled, double-blind study. Two-hundred-and-two dogs with recurrent or non-resectable grade 2/3 MCTs, including 139 dogs with WT c-Kit tumors, received either masitinib (12.5 mg/kg/day) or placebo. Endpoints were tumor response/progression (WHO criteria) and survival.

RESULTS: Masitinib administration resulted in maximal blood concentrations (Cmax: 2µM) above the IC50 for WT c-Kit (100 nM). In dogs with WT c-Kit non-resectable tumors, masitinib significantly improved time-to-progression (TTP) with a median of 140 days (versus 75 for placebo, hazard ratio=1.90, p=0.027). At 12 months, 24.0% of dogs had controlled disease, including 10.0% in complete remission. Moreover, 6.5% of dogs remained in complete remission at 24 months. Masitinib improved survival with a median of 779 days (versus 361 for placebo, hazard ratio: 1.26) and survival rates of 61.3% and 42.6% at 12 and 24 months, respectively (versus 43.8% and 16.7% for placebo, respectively). The efficacy of masitinib was enhanced in first-line therapy with further improved TTP (median: 253 versus 66 days for placebo, hazard ratio=2.73, p=0.008) and tripled survival time (median: 937 versus 286 days for placebo, hazard ratio: 1.73).

CONCLUSIONS: In conclusion, masitinib seems effective in the treatment of non-resectable MCTs expressing WT c-Kit, with enhanced efficacy in first-line therapy.
INTRODUCTION: In oncology, clinical studies often use short-term tumor responses as surrogate endpoints for survival. A two-year follow-up from a pivotal filed study evaluating masitinib, a tyrosine kinase inhibitor (TKI) targeting c-Kit, for canine mast cell tumors (MCT) allowed analyzing the predictivity of short-term tumor responses for survival.

METHODS: Two-hundred-and-two dogs having recurrent or non-resectable grade 2/3 cutaneous MCT without nodal/visceral metastases received oral masitinib (12.5 mg/kg/day) or placebo for 6 months and could extend treatment with tri-monthly visits. Endpoints were tumor response/progression (WHO criteria) and survival.

RESULTS: In dogs with non-resectable MCT, masitinib significantly improved survival rates at 12 (62.1% versus 36.0% for placebo, p=0.024) and 24 months (39.8% versus 15.0% for placebo, p=0.040) and almost doubled survival time with a median of 617 days (versus 322 days for placebo). Moreover, 9% of dogs remained in complete remission at 24 months, suggesting these dogs might be cured. Tumor response at 6 weeks was not predictive of long-term survival (Yule: 0.02, p=0.932). Conversely, tumor control at 6 months was highly predictive (Yule: 0.90, p<0.001 for 24-month survival) showing high specificity (90%) and sensitivity (66%). Tumor response and tumor stabilization at 6 months translated into similar survival confirming that sustainable disease stabilization in MCT was predictive of a good prognosis.

CONCLUSIONS: In conclusion, masitinib significantly improved long-term survival in dogs with nonresectable MCT. Controlled disease at 6 months, but not tumor response at 6 weeks, was predictive of long-term survival, suggesting short-term response may be irrelevant for assessing clinical efficacy of TKIs in MCT.
RESPONSE TO TREATMENT WITH MASITINIB OF CHEMOTHERAPY RESISTANT, METASTASIZED, CANINE CUTANEOUS GRADE 2 AND 3 MAST CELL TUMORS: A PILOT STUDY.

Publication Category: Conference Presentation

Proceedings of the 29th Annual Conference of the Veterinary Cancer Society, October 16-19, 2009
Johan de Vos, Patrick Dubreuil, Alain Moussy, Tom Chapuis, Annette Burm, Lotte van Kuijk, Olivier Hemine

INTRODUCTION: Thirty percent of canine mast cell tumors (MCT’s) display mutations in exon 8, 9, 11 or 17 of c-Kit proto-oncogene. Masitinib is a tyrosine kinase inhibitor, with confirmed efficacy as first-line treatment of canine MCT’s with mutated as well as wildtype c-Kit receptors. Inclusion criteria for this study were dogs with chemotherapy resistant MCT’s.

METHODS: Five dogs with chemotherapy resistant, metastasized, grade 2 and 3 cutaneous MCT’s were treated with masitinib (10-12.5 mg/kg/day). Prior to this treatment, these dogs received prednisolon, vinblastin, lomustin and/or radiation therapy. All MCT’s developed resistance to these treatment modalities. Quality of life of all dogs, previous to masitinib treatment, in fact warranted euthanasia. C-Kit proto-oncogene was sequenced through RTPCR in all five dogs.

RESULTS: In one dog a deletion mutation (DM) and in two dogs an internal tandem duplication (ITD) in exon 11 of c-Kit was detected. The other dogs had wild-type c-Kit. Masitinib induced CR in the dogs with mutated c-Kit. Both dogs with wild-type c-Kit were euthanized shortly after start of masitinib treatment because of MCT progression. In the dogs with ITD, MCT’s recurred after 63 and 92 days, with OST of 79 and 114 days respectively. Post-mortem sequencing was performed in one dog with ITD and revealed an unchanged mutation status. The dog with DM showed no recurrence so far.

CONCLUSIONS: Masitinib appears efficient to induce remission in chemotherapy resistant metastasized canine cutaneous grade 2 and 3 MCT’s with mutated c-Kit.
EVALUATION OF MASITINIB IN THE TREATMENT OF CANINE MAST CELL TUMORS: LONG-TERM FOLLOW-UP EFFICACY DATA FROM PHASE 3 CLINICAL STUDY

Publication Category: Conference Presentation

Proceedings of the Annual Congress of the European Society of Veterinary Oncology, March 26-29, 2009
O Hermine, JP Kinet, P Dubreuil, A Moussy, KA Hahn.

PURPOSE: We evaluated masitinib for the treatment of canine grade 2/3 mast cell tumors (MCT) in multicenter, randomized, placebo-controlled, double-blind study. Previously reported data at 6-month showed that masitinib significantly improved time-to-progression (Log-Rank p=0.033). Here we report a follow-up at 24-months.

DESIGN: Two-hundred-and-two dogs having recurrent or non-resectable grade 2/3 cutaneous MCT without lymph node or visceral metastases received either masitinib (12.5 mg/kg/day, per os, 161 dogs) or placebo (41 dogs). Endpoints were tumor response/progression (WHO criteria) and overall survival (OS).

RESULTS: Two-year follow-up data confirmed the improvement of time-to-progression and showed that masitinib induces long-lasting tumor control. Masitinib was especially efficient on non-resectable tumors. At 12-month, 31.6% of dogs under masitinib had controlled disease (versus no dogs under placebo, p<0.001) and 15.8% were in complete remission. At 24-months, 11.8% of dogs remained in complete remission. Masitinib also improved survival. It increased survival rate at 12-months (61.3% versus 37.5% under placebo, p=0.041) and at 24-months (36.4% versus 15.0% under placebo) and almost doubled the survival time with a median survival of 617 days (versus 322 days under placebo). Masitinib was also particularly efficient on tumors expressing a mutated c-Kit. At 12-month, 31.8% of dogs under masitinib had tumor response (versus no dogs under placebo) and 27.3% were in complete remission. Moreover, at 24-months, 23.8% of dogs remained in complete remission. Masitinib also improved survival. It increased survival rate at 12-months (62.9% versus 1.1% under placebo, p=0.008) and at 24-months (29.3% versus no dogs under placebo) and almost tripled the survival time with a median survival of 498 days (versus 182 days under placebo, hazard ratio: 2.91, p=0.009).

CONCLUSIONS AND CLINICAL IMPORTANCE: Masitinib induced a long-lasting control of tumor progression and was curative (complete remission at 24-months) in a subset of patients. When masitinib was used on nonresectable tumors and on tumors expressing a mutated c-Kit, it was particularly efficient and significantly improved long-term survival.
5.11 ASSESSMENT OF RESPONSE TO THE TREATMENT WITH MASITINIB (MASIVET) OF CHEMOTHERAPY RESISTANT, GRADE 2 AND 3, METASTASIZED CANINE CUTANEOUS MAST CELL TUMORS. REPORT OF FOUR CASES

Publication Category: Conference Presentation

Proceedings of the Annual Congress of the European Society of Veterinary Oncology, March 26-29, 2009
J.P. de Vos, A. Moussy, A. Burm, L. van Kuijk, O. Hermine

INTRODUCTION: c-Kit receptor with the ligand stem cell factor is involved in cell division, differentiation and survival of canine mast cell tumors (MCT). Thirty percent of canine MCT display a mutation in exon 8, 9, 11 or 17 of the c-Kit proto-oncogene. masitinib is a novel tyrosine kinase inhibitor, targeting both c-Kit receptor (mutated and wild type) and PDGFRβ, FGFR3 and FAK pathway.

MATERIAL AND METHODS: Four dogs with chemotherapy resistant, metastasized, grade 2 and 3 cutaneous MCT were treated with masitinib (10-12.5 mg/kg/day p.o.). Prior to the treatment with masitinib, these dogs received several cycles of prednisolone, vinblastin, lomustin and radiation therapy. All MCT became resistant to these treatment modalities. In fact, previous to treatment with masitinib the quality of life of all dogs warranted euthanasia. The mutation status of c-Kit has been analyzed in three of the four dogs.

RESULTS: In one dog a deletion mutation in c-Kit (exon 11) was detected; in the other two no mutation was present. masitinib induced CR in two dogs (one had the c-Kit mutation), with a notable response within seven days after start of therapy. PR and SD were obtained in the dogs with wild-type c-Kit. Treatment duration so far is 45 days. Overall tolerability of masitinib was good, and no side effects were noticed in this small study.

CONCLUSION: masitinib seems an efficient drug to induce remission for chemotherapy resistant grade 2 and 3 MCT. A longer follow up is necessary to evaluate whether the remissions are durable.
**SUMMARY**

Constitutively active forms of c-Kit (a tyrosine kinase receptor regulating mast cell proliferation) carrying juxtamembrane (JM) mutations are expressed in 25% of canine mast cell tumours (MCT) and associated with higher tumour grade and worse prognosis.

Masitinib, a tyrosine kinase inhibitor targeting both wild type (WT) and JM c-Kit was tested for the treatment of recurrent or non-resectable grade 2/3 cutaneous MCT in a multicenter, randomized, placebo-controlled, double-blind study. Endpoints were tumour response/progression (WHO criteria) and overall survival (OS). We previously reported that masitinib was effective in the treatment of MCT in the overall population of dogs. The present report focuses on 139 dogs with tumours expressing WT c-Kit only.

Dogs received either masitinib (12.5 mg/kg/day, per os) or placebo. This masitinib dosage resulted in blood concentrations (Cmin: 100nM – Cmax: 2 µM) above the IC50 for WT c-Kit inhibition (100nM) in pharmacokinetic studies and subgroup efficacy analyses showed that masitinib could be efficient on tumours expressing WT c-Kit.

When used on non-resectable tumours, masitinib significantly improved time-to-progression (TTP) with a median of 140 days (versus 75 days under placebo, Log-Rank p=0.025, hazard ratio=1.93). At 12-months, 28.9% of dogs had controlled disease (versus 0% under placebo, p=0.015) and 11.5% of dogs were in complete remission. Moreover, at 24-months, 6.7% of dogs were still in complete remission. There was a trend for improved survival. Masitinib doubled survival time with a median survival of 779 days (versus 361 days under placebo) and increased survival rate at 12-months (60.7% versus 43.8% under placebo) and 24-months (39.2% versus 23.1% under placebo).

When used as first-line therapy, masitinib significantly improved TTP with a median of 253 days (versus 66 days under placebo, Log-Rank p=0.008, hazard ratio=2.74). At 12-months, 36.4% of dogs had controlled disease (versus 0% under placebo, p=0.04) and 9.1% of dogs were in complete remission. Moreover, at 24-months, 7.1% of dogs were still in complete remission. There was a trend for improved survival. Masitinib tripled survival time with a median survival of 937 days (compared to 286 days under placebo) and increased survival rate at 12-months (69.4% versus 44.4% under placebo) and 24-months (54.8% versus 25.0% under placebo).

In conclusion, masitinib improved tumour control and survival and is therefore indicated in the treatment of MCT expressing WT c-Kit, especially when used on non-resectable tumours or as first-line therapy.
5.13 MASITINIB REDUCES THE ONSET OF METASTASIS AND IMPROVES LONG-TERM SURVIVAL IN DOGS WITH MEASURABLE GRADE 2 AND GRADE 3 MAST CELL TUMOURS.

Publication Category: Conference Presentation

Proceedings of the British Small Animal Veterinary Association Congress, 2009
O Hermine, JP Kinet, P Dubreuil, A Moussy, KA Hahn.

SUMMARY
We evaluated masitinib for the treatment of canine grade 2/3 mast cell tumours (MCT) in multicenter, randomized, placebo-controlled, double-blind study. Previously reported data at 6-months showed that masitinib significantly improved time-to-progression (Log-Rank p=0.033). Here we report data on metastases and follow-up at 24-months. Two-hundred-and-two dogs having recurrent or non-resectable grade 2/3 cutaneous MCT without lymph node or visceral metastases received either masitinib (12.5 mg/kg/day, per os, 161 dogs) or placebo (41 dogs). After 6-months, dogs could extend treatment with tri-monthly tumour assessments. Endpoints were tumour response/progression (WHO criteria) and overall survival (OS).

Masitinib significantly reduced lymph node and visceral metastases. Only 3.7% of dogs under masitinib developed lymph node or visceral metastases (versus 17.1% of dogs under placebo; p<0.001).

Two-year follow-up data confirmed the improvement of time-to-progression and showed that masitinib induces long-lasting tumour control. At 12-months, 23.1% of dogs under masitinib had controlled disease (compared to 5.9% of dogs under placebo, p=0.026) and 11.1% were in complete remission. Moreover, 8.3% remained in complete remission at 24-months.

Masitinib was especially efficient on non-resectable tumours. At 12-month, 31.6% of dogs under masitinib had controlled disease (versus no dogs under placebo, p<0.001) and 15.8% were in complete remission. Moreover, at 24-months, 11.8% of dogs remained in complete remission. Masitinib also improved survival. It increased survival rate at 12-months (61.3% versus 37.5% under placebo, p=0.041) and at 24-months (36.4% versus 15.0% under placebo) and almost doubled the survival time with a median survival of 617 days (versus 322 days under placebo).

Masitinib was also particularly efficient as a first-line therapy. At 12-months, 39.6% of dogs under masitinib had controlled disease (versus no dogs under placebo, p=0.002) and 14.6% were in complete remission. Moreover, at 24-months, 14.3% of dogs remained in complete remission. Masitinib significantly increased survival rate at 12-months (67.9% versus 37.5% under placebo, p=0.042) and 24-months (48.9% versus 14.3% under placebo, p=0.03) and doubled survival time with a median survival of 823 days (versus 322 days under placebo, Log-Rank p=0.021).

In conclusion, masitinib significantly reduced the development of lymph node and visceral metastases, induced a long-lasting control of tumour progression and was curative (complete remission at 24-months) in a subset of patients. When masitinib was used as a first line treatment and/or on non-resectable tumours, it was particularly efficient and significantly improved long-term survival.
5.14 A NOVEL C-KIT INHIBITOR (AB1010) SHOWS THERAPEUTIC POTENTIAL IN DOG MAST CELL TUMORS (DMCT)

Publication Category: Conference Presentation

Proceedings of the 26th Annual Conference of the Veterinary Cancer Society, 2006

SUMMARY
AB1010 is an orally available small molecule that inhibits the juxtamembrane (JM) mutations of c-Kit with a 10-9M IC50. These mutations are associated with the development of DMCT.

An open-labeled Phase II study was performed to determine the therapeutic potential of AB1010. Dogs having measurable cutaneous grade 2 or 3 tumors, with or without metastasis, were evaluated. Thirteen dogs were enrolled with 9 dogs having sufficient treatment duration to evaluate for responsiveness to AB1010. Complete response was observed in 2 of 9 dogs, partial response in 2 of 9 dogs, stable response in 2 of 9 dogs, with 3 dogs having progressive disease. A partial response of the metastatic disease was observed in 2 of 3 dogs. Measurable responses were noted as early as day 7 of the study period. One of the 2 complete responders maintained remission for at least 182 days. The drug was well tolerated and grade 1 neutropenia was occasionally observed without consequences.

A randomized, double blinded, placebo-controlled, Phase III study is on going to confirm the clinical efficacy of AB1010. Main criteria for inclusion are: (1) non-resectable tumors or recurrent tumors following surgery (2) histopathologic grade 2 or 3 (3) no internal metastasis or lymph node involvement. To date, 170 dogs have been recruited. Complete results will be available in 2007. Genotyping of 40 tumors has been accomplished. Results show c-Kit expression in 100% of the tumors with less than 50% expressing the JM mutations. Furthermore preliminary clinical data strongly suggest that WT-c-Kit expressing tumors are also sensitive to AB1010. Taken together, our data indicate that other oncogenic mechanisms must be involved in the formation of DMCT, some of which appear to be sensitive to AB1010.
6 OTHER CANINE ONCOLOGY

6.1 POSITIVE RESPONSE IN THE TREATMENT OF EPITHELIOOTROPIC T-CELL LYMPHOMA (MYCOSIS FUNGOIDES) WITH MASITINIB

Publication Category: Conference Presentation

Proceedings of the Annual Congress of the European Society of Veterinary Oncology, March 24-26, 2011.
Jagielski D, Chapuis T, Lebruneau J, Hermine O

INTRODUCTION: Masitinib is an oral tyrosine kinase inhibitor that selectively targets c-Kit and PDGFR. In-vitro studies have shown that T-cell lymphoma cells are particularly sensitive to the anti-proliferative action of masitinib. In humans, mycosis fungoides has shown positive immunohistochemistry reaction for both PDGF and PDGFR in the abnormal cells.

MATERIAL AND METHODS: A 10.5 year-old Dachshund, female with diagnosed T-cell epitheliotropic lymphoma showed relapse with severe skin inflammation, erythema, alopecia and pruritus after COP chemotherapy (3 months partial response), and lomustine with prednisone (3 months partial response). Masitinib was administered in monotherapy at a dose of 12.5 mg/kg/day.

RESULTS: Following 1 week of masitinib treatment a significant improvement in skin and general condition was observed, with a complete response documented after 3 weeks. Throughout the duration of treatment an improvement in the patient’s quality of life was also observed. After 4 months the patient was lost to follow-up due to death, likely due to anemia without clear causality. No postmortem examination was performed. Immunohistochemistry on the biopsy showed intense staining for phosphorylated PDGFRβ and discrete staining for PDGFRα, consistent with human findings.

CONCLUSIONS: Tumor cell-derived PDGF may play an important role in tumorigenesis. Hence, selective inhibition of PDGFR with subsequent apoptosis of abnormal cells might explain the observed positive response to masitinib. Together with supporting in-vitro findings this suggests that masitinib might represent a therapeutic option for dogs with T-cell epitheliotropic lymphoma. Further study is required to classify the morphological type of the neoplastic lymphocytes, and to assess treatment efficacy in a larger study cohort.
6.2 MASITINIB FOR MAINTENANCE CHEMOTHERAPY OF TWO DOGS WITH T-CELL MULTICENTRIC LYMPHOMA

Publication Category: Conference Presentation

Proceedings of the Annual Congress of the European Society of Veterinary Oncology, March 18-20, 2010
F Serres, C Meyer, D Tierny, A Hidalgo, C Haelewyn, L Marescaux

SUMMARY

Response to treatment of canine T-cell multicentric lymphoma is classically described as poor, especially for pleomorphic and lymphoblastic forms, with median survival times of less than 8 months in most studies focusing on the interest of «conventional» chemotherapy. In vitro studies have shown that canine T-cell might be sensitive to masitinib, owing to the inhibition of c-Kit/PDGFRα&β.

Two Shih-tzu female dogs were presented for clinical staging and evaluation of therapeutic possibility in multicentric lymphoma. Dogs were clinically staged 3-a and cytologic examination of enlarged lymph nodes was suggestive of clear cell lymphoma (CCL) and large granular lymphoma (LGL), respectively. Immunostaining was positive for CD-3 and negative for CD-79, indicating a T-Cell origin. Both dogs had been previously treated with glucocorticoids. The dog with CCL initially received vincristin (as part of a CHOP based protocol), but treatment was poorly tolerated and the owner withdrew consent prior to the induction period. The dog with LGL received one initial administration of L-asparaginase. Both dogs received masitinib (12 and 12,2 mg/kg/day, respectively) after this initial induction period.

Masitinib was well tolerated (clinically and according to haematology, serum biochemistry and urinanalysis). Progressive complete remission was reached in the dog with CCL, which remained present at the time of writing, 8 months after initial diagnosis. Rapid complete remission was reached in the dog with LGL, which remained present at the time of writing, 3 months after initial diagnosis.

Masitinib was well tolerated and could represent a therapeutic option in dogs with T-Cell multicentric lymphoma.
6.3 A C-KIT INHIBITOR (MASIVET®) SHOWS THERAPEUTIC POTENTIAL IN DOG NEUROFIBROSARCOMA

Publication Category: Conference Presentation

Proceedings of the Annual Congress of the European Society of Veterinary Oncology, March 18-20, 2010
A Roos, S Fraytag, A. Moussy, O. Hermine.

BACKGROUND
An 11 year-old, mixed breed, female dog was diagnosed with neurofibrosarcoma in October 2007. The tumour recurred despite two prior surgeries, chemotherapy with doxorubicine and metronomic chemotherapy (endoxan/meloxicam). A strong relationship exists between the pathogenesis of neurofibrosarcoma and both mast cells and Schwann cells. This suggests possible benefits from treatment with targeted c-Kit or PDGFR inhibitors, respectively. Masitinib (Masivet®) is a tyrosine kinase inhibitor (TKI) that potently and selectively inhibits PDGFR and c-Kit, as well as Lyn and Fyn, without inhibiting kinases of known toxicities.

METHODS
Neurofibrosarcoma was diagnosed by histological analysis. Mast cell infiltration was evidenced by c-Kit and tryptase staining. Treatment with Masivet® was initiated in April 2009 with 12 mg/kg/day administered orally. No concomitant treatments were administered and the patient was careful monitored for adverse events.

RESULTS
The tumour was infiltrated by scattered mast cells at the vicinity of blood vessels. Signs of superficial necrosis were visible at day-4 of treatment. At week-3 a reference mass was measured to be 5x4cm, which at week-6 had shrunk to 3x2cm and was negligible at week-10. However, new masses may indicate a higher dosage is required to control tumour metastases. No adverse events were reported, with only a minor decrease in protein level.

CONCLUSION
This represents the first reported case of canine neurofibrosarcoma being treated with the TKI Masivet®. Rapid tumour growth was quickly stabilised followed by a significant decrease in volume; treatment was well tolerated. There is compelling motivation to conduct further preclinical (mechanistic, resistance) and clinical (efficacy and safety) studies.
INTRODUCTION: Haemangiosarcoma (HSA) cells have been shown to express c-kit (CD117), flk-1 (VEGFR2), constitutively activated platelet-derived growth factor receptor-β (PDGFR-β) and anti-apoptotic factors such as bcl-2 and survivin. In dogs with HSA, increased levels of vascular endothelial growth factor (VEGF) have been documented, suggesting a mechanism for early metastatic disease. Masitinib mesylate is a tyrosine kinase inhibitor that selectively targets c-kit and PDGFR-α/β, as well as other tyrosine kinases.

The purpose of this study was to determine the IC50 of masitinib in HSA cells, investigate masitinib’s ability to induce apoptosis in HSA cells and finally its capacity to modulate VEGF expression when these cells are exposed to masitinib.

METHODS: Three HSA cell lines (DEN, Fitz and SB) were treated with increasing concentrations of masitinib mesylate (0.01–100 µM) for 24, 48 and 72 h. The IC50 was determined using a Cell Titer Blue® cell viability assay. Apoptosis was measured using the Apo-ONE® Homogeneous caspase-3/7 assay. Levels of VEGF at 72 h were evaluated using a Quantikine® canine VEGF immunoassay.

RESULTS: The IC50 for DEN, Fitz and SB were determined to be 8.56, 9.41 and 10.65 µM, respectively. Apoptosis was shown to increase in correlation with the IC50 consistently in each cell line. VEGF levels increased in close proximity to the IC50 of each cell line.

CONCLUSIONS: Masitinib mesylate causes dose-dependent HSA cell death. One mechanism of cell death due to masitinib mesylate is caspase-mediated apoptosis. The significance of elevations of VEGF prior or concurrently with apoptosis and cell death requires further investigation.
MASITINIB, ORAL TYROSINE KINASE INHIBITOR, IN THE TREATMENT OF ADVANCED MELANOMA: PRECLINICAL PROOF-OF-CONCEPT AND PHASE 1/2/3 STUDY DESIGNS.

Publication Category: Conference Presentation

O. Hermine, Douglas Thamm, M Humbert, S Letard, A. Moussy, Patrice Dubreuil

SUMMARY
The continuing poor prognosis and lack of effective treatments for non-resectable or metastatic stage 3/4 melanoma highlight an unmet medical need in human and veterinary medicine. It is crucial therefore, to identify alternative or complementary treatment strategies that improve the clinical management and prognosis of patients afflicted with this cancer.

Masitinib is an oral tyrosine kinase inhibitor (TKI) that in vitro has greater activity and selectivity against c-Kit than imatinib. It is particularly efficient in controlling the proliferation, differentiation and degranulation of mast cells; cells that are involved in several mechanisms that facilitate tumour growth. Masitinib also potently targets PDGFR, Lyn and to a lesser extent the FAK pathway, without inhibiting kinases of known toxicities. Respectively, these kinases are associated with: modulating tumoural interstitial pressure and thus, chemotherapy uptake; regulation of cell signalling, adhesion, migration, apoptosis, cell cycle progression and resistance to conventional therapies; and the transduction pathway leading to mast cell IgE induced degranulation. Moreover, in vivo and in vitro studies have shown that masitinib can enhance the antiproliferative effects of chemotherapeutic agents to various human and canine cancer cell lines.

Specific melanomas have been shown to bear c-Kit aberrations (either mutation or amplification), strongly suggesting that a c-Kit inhibitor such as masitinib could be of therapeutic benefit to this subpopulation. Moreover, there is evidence that this targeted therapy can exert an anticancer action that extends beyond its inherent TKI profile, i.e. through the reduction of tumour progression and/or improved drug delivery and/or the inhibition of mast cell migration and activation.

We investigated masitinib’s potential to sensitize canine melanoma cell lines to chemotherapies using in vitro proliferation assays. Masitinib sensitized doxorubicin-sensitive (CML-6M and CML-10C2) cells, as well as resistant (17CM98) melanoma cells to doxorubicin (≥6-fold reduction in IC$_{50}$ at 5 to 10 µM masitinib). These data establish proof-of-concept that masitinib can sensitize canine melanoma tumour cell lines to doxorubicin; as well as cisplatin and gemcitabine to a lower extent in CML-6M. Further confirmation of masitinib’s therapeutic potential for this cancer is observed in veterinarian case studies, including a dog with histologically proven metastatic melanoma that was unresponsive to chemotherapy but showed a complete response after introduction of masitinib.

Based upon these studies (as well as successful clinical trials for masitinib treatment of canine MCT, human GIST and advance pancreatic cancer in combination with gemcitabine) two human clinical trials of masitinib treatment for non-resectable or metastatic stage 3/4 melanoma will be initiated in 2010. The first is a prospective, multicentre, open-label, uncontrolled, phase 1/2 study to evaluate masitinib in combination with dacarbazine in the treatment of patients not carrying a mutation in the juxta membrane domain of c-Kit. The second is a multicentre, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare masitinib to dacarbazine in the treatment of patients carrying a mutation in the juxta membrane domain of c-Kit.
THE CYTOTOXIC EFFECT OF MASITINIB (MASIVET8) ON A CANINE LEUKEMIA CELL LINE DOES NOT RESULT FROM INHIBITION OF THE ABC-TRANSPORTERS P-GP AND MRP-1

Publication Category: Conference Presentation

Proceedings of the 23rd European College of Veterinary Internal Medicine-Companion Animals, September 2010
Maurice Zandvliet, Erik Teske, Johanna Fink-Giemimels, Jan Schrickx

INTRODUCTION: Tumour cell resistance to chemotherapeutic agents is the main reason for treatment failure in canine malignant lymphoma. Resistance to doxorubicin, one of the most potent chemotherapeutic agents available, is associated with resistance to other chemotherapeutic agents, a phenomenon known as Multi-Drug Resistance (MDR). One of the possible mechanisms of MDR is overexpression of drug-transporters of the ATP-Binding Cassette superfamilly. In vitro work with masitinib, a tyrosine kinase inhibitor licensed for the treatment of mast cell tumors, showed that this drug has a cytotoxic effect on lymphoblasts and the ability to reverse MDR in multiple cell lines. As a result masitinib could potentially have a role in the treatment of dogs with MDR lymphoma. The underlying mechanism for reversal of MDR is unknown and the authors hypothesized that this is the result of inhibition of ABC-transporters.

MATERIALS AND METHODS: The GL-1 cell line, a canine leukemia cell line, was transformed into a doxorubicin-resistant subline (GL-40) by continuous incubation with gradually increasing concentrations of doxorubicin. By measuring retention of the substrates rhodamine123, calcein-AM and CFDA, the effect of increasing concentrations of masitinib was tested on Pgp and MRP-1 function in both GL-1 and GL-40. Cellular retention of fluorescent substrates and doxorubicin was analysed by FACS after 30 minutes of incubation with or without inhibitors.

RESULTS: At higher concentrations masitinib has a cytotoxic effect on the canine leukemia cell lines GL-1 and GL-40. Masitinib is an inhibitor of both P-GP and MRP-1 in GL-40. Inhibition of these ABC-transporters did not result in increased intracellular doxorubicin concentrations.

DISCUSSION: Masitinib is cytotoxic to canine leukemia cells. Although masitinib has an inhibitory effect on P-gp and MRP activity, this does not result in an increased intracellular doxorubicin retention. Therefore masitinib does not reverse MDR by inhibition of these ABC-transporters. Potential mechanisms to explain the observed results require additional studies.
INTRODUCTION: In vitro, masitinib sensitizes several canine tumor cell lines to doxorubicin. A phase I clinical study evaluated the safety of masitinib + doxorubicin in dogs with advanced tumors.

METHODS: Dogs first received masitinib (12.5 mg/kg/day PO) for 2 weeks; the masitinib was continued concurrently with at least two cycles of doxorubicin (one cycle=3 weeks). Successive cohorts of three dogs were enrolled. The first cohort received masitinib + doxorubicin (25 mg/m2 for dogs =15 kg or 0.8 mg/kg for dogs <15 kg, q3w). Doxorubicin dose escalation was considered for successive cohorts using a modified Fibonacci dose escalation scheme.

RESULTS: One dog was withdrawn for a renal adverse event before receiving doxorubicin and sixteen received masitinib + doxorubicin: eight dropped out prematurely for disease progression, six completed the study and two received higher than intended doses of doxorubicin. Three dogs received masitinib + doxorubicin (25 mg/m2 for dogs =15 kg or 0.8 mg/kg for dogs <15 kg, q3w). All completed two cycles without experiencing dose limiting toxicity (DLT). Three dogs received masitinib + doxorubicin (30 mg/m2 for dogs =15 kg or 1 mg/kg for dogs <15 kg, q3w). Two dogs completed two cycles without experiencing DLTs and one experienced a DLT (neutropenia). Two dogs (<15 kg) received higher than intended doses of doxorubicin (1.28 and 1.17 mg/ kg q3w, respectively). Both experienced DLTs.

CONCLUSIONS: The maximum tolerated dose of doxorubicin in combination with masitinib (12.5 mg/kg/day) was at least 30 mg/m2 for dogs =15 kg and 1 mg/kg for dogs <15 kg.
6.8 EVALUATION OF SAFETY OF MASITINIB IN COMBINATION WITH CARBOPLATIN IN ADVANCED CANINE TUMORS

Publication Category: Conference Presentation
Greg Ogilvie, Anthony Rusk, Alfred Legendre, Alain Moussy, Olivier Hermine

INTRODUCTION: Preclinical data suggest that masitinib sensitizes several canine tumor cell lines to carboplatin. A phase I clinical study evaluated the safety of masitinib associated with carboplatin in dogs with advanced tumors.

METHODS: Dogs first received masitinib (12.5 mg/kg/day PO) for 2 weeks; the masitinib was subsequently continued and given concurrently with at least two cycles of carboplatin (one cycle=3 weeks). Successive cohorts of three dogs were enrolled. The first cohort received masitinib + carboplatin (250 mg/m2 IV, q3w). Carboplatin dose escalation was considered for successive cohorts using a modified Fibonacci dose escalation scheme.

RESULTS: Six dogs with advanced tumors were recruited and received masitinib + carboplatin. Four dogs completed the study and two were withdrawn due to disease progression. The first three dogs received masitinib + carboplatin (250 mg/m2 IV q3w). Two dogs completed the two cycles without experiencing any dose-limiting toxicity (DLT) and one died because of disease progression during the third week of treatment. The next three dogs received masitinib + carboplatin (300 mg/m2 IV q3w). Two dogs completed the two cycles without experiencing any DLT and one dog had disease progression before receiving combination therapy. This dog received the first cycle of carboplatin but discontinued treatment before completing the two cycles because of disease progression.

CONCLUSIONS: For each cohort, two out of three dogs completed the two cycles of carboplatin in combination with masitinib without experiencing DLT. Therefore, the maximum tolerated dose of carboplatin in combination with masitinib (12.5 mg/kg/day) was at least 300 mg/m2.
7 CANINE ATOPIC DERMATITIS

7.1 MASITINIB DECREASES SIGNS OF CANINE ATOPIC DERMATITIS: A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL

Publication Category: Peer Reviewed Journal (Full manuscript available in appendices or upon request to AB Science - contact@ab-science.com)


SUMMARY

This study investigated the efficacy and safety of masitinib, a selective tyrosine kinase inhibitor capable of downregulating mast cell functions, for treatment of canine atopic dermatitis (CAD). Dogs with confirmed CAD received masitinib at 12.5 mg/kg/day (n = 202) or control (n = 104) for 12 weeks. A reduction in CAD Extent and Severity Index (CADESI-02) score of 50% at week 12 was observed in 61% of masitinib-treated dogs versus 35% of control dogs (P < 0.001), according to the modified intent-to-treat population, observed cases data set (quoted hereafter unless stated otherwise). The corresponding result according to the missing considered as failure data set was 43 versus 26%, respectively (P < 0.001). For dogs resistant to ciclosporin and/or corticosteroids (60% of the study population), CADESI-02 response rates were 60 versus 31%, respectively (P = 0.004). The mean reduction in pruritus score of severely pruritic dogs was 46 versus 29%, respectively (P = 0.045). Furthermore, 65% of owners with severely pruritic dogs assessed masitinib efficacy as good/excellent versus 35% control (P = 0.05). Overall, 63% of investigators assessed masitinib efficacy as good/excellent versus 35% control (P < 0.001). Premature discontinuations from the modified (intent-to-treat) population (28.2% masitinib versus 26.0% control) were mainly due to adverse events (13.4 versus 4.8%, respectively) or lack of efficacy (12.4 versus 18.3%, respectively). In total, 13.2% dogs presented with severe adverse events (16.0% masitinib versus 7.7% control). Masitinib showed a risk of reversible protein loss, although regular surveillance of blood albumin and proteinuria allowed for discontinuation of treatment while the dog was still clinically asymptomatic. Masitinib proved to be an effective and mostly well-tolerated treatment of CAD, including severe and refractory cases, with medically manageable adverse effects.
**INTRODUCTION:** Masitinib is a tyrosine kinase inhibitor that potently and selectively targets c-Kit and Lyn, therefore, down-regulating mast cell functions.

**METHODS:** Randomized (2:1), double-blinded trial, 44 centers in Europe and the USA. Dogs with a confirmed diagnosis of CAD (CADESI-02 ≥25), regardless of pruritus score, were eligible. Dogs received masitinib (12.5mg/kg/day) or placebo for 12 weeks with concomitant flea treatment. A restrictive list of prescribed antimicrobial/antifungal/antiseptic treatments was permitted.

**RESULTS:** A reduction in CADESI-02 of >50% was observed in 61% of masitinib-treated dogs (N=202) vs. 35% placebo (N=104); (p<0.001, observed cases at W12 [OC]). For dogs resistant to cyclosporine and/or corticosteroids (60% of population), CADESI-02 response rates were 60% vs. 31%, respectively (p=0.004, OC). The mean reduction in pruritus score of severely pruritic dogs was 46% vs. 29%, respectively (p=0.045, OC), with the related CADESI-02 excoriation sub-score showing improvement for masitinib and deterioration in placebo (-34% vs. +35%, respectively). Furthermore, 65% of owners with such dogs assessed masitinib efficacy as good/excellent vs. 35% placebo (p=0.05, OC). Overall, 63% of investigators assessed masitinib efficacy as good/excellent vs. 35% placebo (p<0.001, OC). Concomitant treatments with antimicrobials and/or antiseptics were required more frequently in the placebo group (p=0.055). Premature discontinuations (28.2% masitinib vs. 26.0% placebo) were mainly due to adverse events (13.3% vs. 4.8%, respectively) or lack of efficacy (12.4% vs. 18.3%, respectively). In total, 15.2% dogs presented with severe adverse events (18.0% masitinib vs. 9.6% placebo), including 1.9% deaths (1.4% vs. 2.9%, respectively).

**CONCLUSIONS:** Masitinib proved to be an effective treatment of CAD, even in dogs resistant to current therapies, with medically manageable side-effects.
THE TYROSINE KINASE INHIBITOR MASITINIB (MASIVET®) IS EFFECTIVE FOR TREATMENT OF ATOPIC DERMATITIS IN DOGS

Publication Category: Conference Presentation

New Trends in Allergy VII Congress. Special Workshop: Atopic Dermatitis in Dogs, 2010

SUMMARY
The long term treatment of canine atopic dermatitis (CAD) remains an unmet medical need, especially in severe and refractory cases. Mast cells (MC) are known to produce a variety of inflammatory mediators that are in part responsible for the complex inflammatory cascade associated with allergic disease. As such, MCs represent an attractive, hitherto untapped, therapeutic target for CAD.

Masitinib is a tyrosine kinase inhibitor that potently and selectively targets c-Kit and Lyn, and consequently down-regulates MC functions. Proof-of-concept that masitinib can safely reduce symptoms associated with inflammatory diseases in veterinary and human medicines have been demonstrated via Phase 1/2 studies (e.g. human asthma, arthritis, psoriasis; feline asthma and CAD).

Reported are results from a randomised, controlled, pivotal phase 3 trial, to compare efficacy and safety of masitinib at 12.5 mg/kg/d to placebo in the treatment of CAD over 12 weeks. Dogs with a confirmed diagnosis of CAD (CADESI-02 ≥25), regardless of pruritus score, were eligible. A reduction in CADESI-02 of >50% was observed in 61% of masitinib-treated dogs (N=202) vs.35% placebo (N=104); (p<0.001, observed cases at W12 [OC]). For dogs resistant to cyclosporine and/or corticosteroids (60% of population), CADESI-02 response rates were 60% vs.31%, respectively (p=0.004, OC). The mean reduction in pruritus score of severely pruritic dogs was 46% vs.29%, respectively (p=0.045, OC). Furthermore, 65% of owners with such dogs assessed masitinib efficacy as good/excellent vs.35% placebo (p=0.05, OC). Overall, 63% of investigators assessed masitinib efficacy as good/excellent vs.35% placebo (p<0.001, OC). In total, 15.2% dogs presented with severe adverse events (18.0% masitinib vs.9.6% placebo), including 1.9% deaths (1.4% vs.2.9%, respectively).

Masitinib proved to be an effective and safe treatment of CAD, even in dogs resistant to current therapies, with medically manageable side-effects.
7.4 MASITINIB FOR THE TREATMENT OF CANINE ATOPIC DERMATITIS: A PILOT STUDY

Publication Category: Peer Reviewed Journal (Full manuscript available in appendices or upon request to AB Science - contact@ab-science.com)

Daigle J, Moussy A, Mansfield CD, Hermine O.

SUMMARY
There is an on-going need to identify medications suitable for the long-term treatment of canine atopic dermatitis (CAD). Masitinib mesilate is a potent and selective tyrosine kinase inhibitor of the c-KIT receptor. A strong relationship exists between the SCF/c-KIT pathway and pathogenesis of CAD, suggesting that masitinib may potentially fulfil the above role. This study reports on an uncontrolled pilot study of masitinib in CAD. Masitinib was administered orally to 11 dogs at a mean dose of 11.0 +/- 1.83 mg/kg/day (free base) for 28 days. Treatment response was assessed by evolution of clinical appearance according to a modified version of the Canine Atopic Dermatitis Extent and Severity Index (mCADESI), pruritus scale and surface area of lesions. Masitinib improved CAD with a mean reduction in mCADESI of 50.7 +/- 29.8% (95% C.I. = 29.4-72.0; p = 0.0004) at day 28 relative to baseline, with 8/10, 8/10 and 4/10 dogs showing improvement of >=33%, >=40% and >=50%, respectively. Improvement was further evidenced by a decrease in pruritus score and the surface area of lesions. No serious or severe adverse events occurred during this trial, although 6/11 dogs presented with mild to moderate treatment related adverse events. There is sufficient compelling evidence to warrant further investigation.
Efficacy and Safety of Masitinib on the Treatment of Atopic Dermatitis in Dogs

Publication Category: Conference Presentation

2008 North American Veterinary Dermatology Forum (April 9-12, 2008 – Denver, Colorado United States)
K. Beale, J. Daigle, P. S. Leventhal, P. Dubreuil, A. Moussy, O. Hermine

SUMMARY
We previously described masitinib, a protein-tyrosine kinase inhibitor targeting c-Kit, the receptor for stem cell factor, which is a key regulator of mast cell differentiation and proliferation. Mast cells are well known to participate in the pathophysiology of atopic dermatitis, a very common disease in dogs. Therefore, in the current study, we explored the efficacy of masitinib in treating canine atopic dermatitis.

This was a Phase 2 non-controlled pilot study performed in two centers. The study including a total of 11 dogs (6 male, 5 female) between 0.9 and 7.9 years of age presenting with atopic dermatitis according to Prelaud’s criteria. The dogs received daily oral treatment for 4 weeks with 10 mg/kg/day of masitinib free base, with dose adjustments according to efficacy and appearance of toxicity. The canine atopic dermatitis extent and severity index (CADESI) and the lesion surface (% of body area) were determined on days 0, 14, and 28, a pruritus score (0 to 4) was calculated on days 0 and 28, and toxicity was assessed by blood tests on days 14 and 28 as well as by clinical observations.

The mean total CADESI improved by 38.3 ± 29.2% (P=0.0025 [n=10]) and 50.7 ± 29.8% (P=0.0025 [n=10]) at days 14 and 28, respectively. An improvement ≥ 33%, 40%, and 50% was observed in 8/10, 8/10, and 4/10 of the patients, respectively. CADESI subscores for erythema (19.0 ± 15.2 vs 34.7 ± 12.5 [P=0.005]), lichenification (2.6 ± 2.5 vs 9.3 ± 9.8 [P=0.0371]), excoriation (2.9 ± 2.4 vs 9.9 ± 7.0 [P=0.0177]), and scraping alopecia (10.5 ± 13.6 vs 22.6 ± 22.9 [P=0.0177]) were significantly improved at day 28, although the subscore of papules did not change (10.1 ± 11.3 vs 11.3 ± 12.3 [P=0.5086]). Between days 0 and 28, the change in pruritus score was −2 for 3/10, −1 for 2/10, 0 for 3/10, and +1 for 2/10 patients. In 4 of the 5 patients with unchanged or increased pruritus score, the total CADESI decreased. In addition, there was a decrease in the surface area of lesions between days 0 and 28. Ten adverse events were reported in 7 of the 11 dogs, and there were no severe adverse events. Only one adverse event associated with the study drug (febrile episode lasting 2 days) led to treatment arrest, and it resolved without sequelae. An expected decrease of white blood cells related to the effect of the study drug was observed, although, when present, neutropenia was of mild or moderate severity.

These results show that the treatment was safe and effective for canine atopic dermatitis. Accordingly, a Phase 3 study to confirm these findings is warranted.
8.1 SAFETY OF MASITINIB MESYLAATE IN HEALTHY CATS

BACKGROUND: Masitinib mesylate is a PO-administered tyrosine kinase inhibitor developed both for human and animal diseases with activity against both mutated and wild type forms of the c-kit receptor and platelet-derived growth factor receptors α and β, and is currently registered in Europe for the treatment of mast cell tumors in dogs.

HYPOTHESIS/OBJECTIVES: The objective of this study was to determine if healthy cats can tolerate administration of masitinib without clinically relevant adverse effects. Animals: Twenty healthy research colony-specific pathogen-free cats.

METHODS: This study was a prospective, randomized phase 1 clinical trial. Masitinib was administered PO to 20 healthy cats. Ten cats received 50 mg masitinib every other day for 4 weeks, and 10 cats received 50 mg masitinib daily for 4 weeks.

RESULTS: Clinically relevant proteinuria was noted in 2/20 (10%) cats (both treated daily), and neutropenia was noted in 3/20 (15%) (seen in both treatment groups). An increase in serum creatinine concentration and adverse gastrointestinal effects were noted in some cats.

CONCLUSIONS AND CLINICAL IMPORTANCE: Masitinib mesylate was tolerated in the majority of cats. Long-term administration and pharmacokinetic studies are needed to further assess the use of masitinib in cats.
8.2 PHARMACOKINETICS OF MASITINIB IN CATS

Publication Category: Peer Reviewed Journal (Full manuscript available in appendices or upon request to AB Science - contact@ab-science.com)

Vet Res Commun 2009; 33:831–837
Bellamy F, Bader T, Moussy A, Hermine O.

SUMMARY
Masitinib is the first veterinary drug recently approved in Europe to treat mast cell tumours in dogs. This inhibitor is selective and highly efficient in blocking c-Kit, PDGFR, and Lyn tyrosine kinase activities. It showed good efficacy and acceptable toxicity in several animal studies such as mice, rats, rabbits and dogs. C-kit is a tyrosine kinase receptor that plays a critical role in the biology of mast cells including differentiation, survival, migration and cytokine/mediator release. Mast cells are involved in a number of allergy-and immune-related diseases in cats such as asthma, inflammatory bowel disease, and feline mast cell tumours. Therefore, there might be a strong rationale to use masitinib in these indications. Here, we report the results of a preliminary pharmacokinetic study of masitinib in cats which showed a good bioavailability of ~60% in both sexes. We propose that an oral dose of 10-15 mg/kg masitinib is appropriate to achieve adequate plasma concentrations.
8.3 A RANDOMIZED, BLINDED, PLACEBO-CONTROLLED STUDY OF THE TYROSINE KINASE INHIBITOR MASITINIB FOR TREATMENT OF EXPERIMENTAL FELINE ASTHMA

Publication Category: Conference Presentation

Proceedings of the 28th Veterinary Comparative Respiratory Symposium in Raleigh, North Carolina 2010
Tekla M. Lee-Fowlera, Vamsi Gunturb, John Dodama, Leah A. Cohna, Amy E. DeCluea, Carol R. Reineroa

SUMMARY
Tyrosine kinase inhibitors (TKI) represent a novel treatment for asthma. We hypothesized that the TKI masitinib would decrease airway inflammation and hyperreactivity with minimal toxicity in experimental feline allergic asthma.

Twelve asthmatic cats received 50mg/day masitinib or placebo orally for 12 weeks. Bronchoalveolar lavage fluid (BALF) % eosinophils and airway hyperreactivity in response to methacholine (MCh) challenge using ventilator acquired mechanics were determined. Results of MCh challenges were reported as the effective MCh concentration that increased baseline airway resistance by 200% (EC200Raw) and the end-inspiratory pressure after a breath hold (plateau pressure (Pplat)). Treatment was interrupted if predetermined adverse events were noted.

Baseline group mean±SD % BALF eosinophils were not significantly different between treatments (masitinib, 46±24%; placebo, 44±22%; p=0.345). After 4 weeks, the group mean±SD % BALF eosinophils was significantly lower in cats receiving masitinib compared with placebo (7±9% and 30±27%, respectively; p=0.023). There was no significant difference in the group mean±SD EC200Raw between groups at baseline or at 4 weeks. However, after 4 weeks, the Pplat with MCh challenge significantly (p=0.016) increased in placebo but not masitinib-treated cats (p=0.32). Masitinib-treated cats were significantly more likely to develop proteinuria (p=0.001) leading to drug interruption or withdrawal from study. Proteinuria was self-limiting in all cases after discontinuation of drug.

Masitinib at 50mg/cat/day significantly reduced eosinophilic airway inflammation and blunted one index of MCh-induced airflow limitation (Pplat) after 4 weeks. Adverse effects (specifically proteinuria), while reversible on discontinuation of drug, were common.
INTRODUCTION: Platelet derived growth factor receptor (PDGFR) has been shown to play a role in the growth and viability of vaccine-associated sarcoma (VAS) cells. Masitinib is a tyrosine kinase inhibitor that specifically targets multiple growth factor receptors including PDGFR. The objective of this study was to evaluate the in vitro effects of masitinib on VAS cell proliferation, apoptosis and PDGFR phosphorylation.

METHODS: VAS cell lines were derived at our institution from a primary tumor and a corresponding, histologically confirmed, VAS lung metastasis. PDGFR expression was confirmed by Western blot and flow cytometry (FACScan) analysis. Masitinib (0-100 AM, generously provided by AB Science) was co-cultured with each cell line to generate dose response curves measured by Alamar BlueTM cell viability/proliferation assays. Cellular apoptosis was assessed by 7-AAD flow cytometry. Masitinib-mediated suppression of PDGF-induced phosphorylation of PDGFR was evaluated by immunoprecipitation/Western blot assays. All experiments were performed in triplicate.

RESULTS: Masitinib resulted in a marked decrease in cell proliferation and an increase in apoptosis in a dose-dependent fashion. Growth inhibition and apoptosis correlated with the inhibition of PDGFR tyrosine phosphorylation in both cell lines.

CONCLUSIONS: These findings suggest that masitinib represents a growth-inhibitory agent that can influence cellular proliferation, apoptosis and PDGFR activation in VAS. This supports further investigation of masitinib as a novel therapeutic agent to treat VAS in cats.
INTRODUCTION: Masitinib mesylate is an oral receptor tyrosine kinase inhibitor (RTKI) developed for the veterinary market with activity against both mutated and wild type forms of the c-kit receptor (CD117), platelet derived growth factor receptors α and β (PDGFR), as well as various other receptors. Both fibroblastic growth factor receptors and PDGFRs are often altered in vaccine associated sarcomas in the cat. The purpose of this study was to evaluate growth inhibition, radiosensitization, and chemosensitization of two feline sarcoma cell lines exposed to masitinib mesylate and to establish the safety of clinically relevant doses in healthy cats.

METHODS: Two feline sarcoma cell lines were evaluated in this study. Reverse transcriptase polymerase chain reaction (RT-PCR) evaluation for CD117 and PDGFR was performed. Cells were incubated with varying concentrations of masitinib and evaluated. Masitinib treated and untreated cells were exposed to 5 Gy Cobalt 60 radiation. Treated and untreated cell lines were exposed to doxorubicin and carboplatin. Cell survival was determined using flow cytometry. In healthy cats, 3 cats were started at a dose of 50 mg masitinib (12.5 mg/kg) every other day. A CBC, Chemistry, UA, UPC and blood pressure were collected from each cat at various time points. Daily physical examinations were performed.

RESULTS: Both cell lines were shown to express CD117 and PDGF receptors. Growth inhibition was seen due to masitinib treatment under the various conditions in the cell lines.

CONCLUSIONS: Masitinib has potential as an anti neoplastic agent in the cat for use against vaccine associated sarcomas as well several other diseases.
9 MISCELLANEOUS CANINE AND FELINE TREATMENTS

9.1 MASITINIB – A TARGETED THERAPY WITH APPLICATIONS IN VETERINARY ONCOLOGY AND INFLAMMATORY DISEASES

Publication Category: Peer Reviewed Journal (Full manuscript available in appendices or upon request to AB Science - contact@ab-science.com). A pre-publication author version is also available to download from the following weblink: [DOWNLOAD HERE](https://docs.google.com/viewer?a=v&pid=explorer&chrome=true&srcid=0B4Of9Adq406YoA5Y2FinNWEyJU1NyO0MGVILh2ZQrNDQzMyY3NDgsNTI4&hl=en_US]

GK Ogilvie, P Hensel, BE Kitchell, P Dubreuil, and A Ahn

SUMMARY
Tyrosine kinase inhibitors (TKIs) are an innovative class of drug, which have recently become available to veterinary medicine. This targeted therapy inhibits enzymes involved in cellular signaling pathways that regulate key cell functions and cell survival. Over the last decade, TKIs have revolutionised the management of certain human cancers and are now making inroads into veterinary medicine, with canine mast cell tumor (MCT) being their first major success story. TKIs used in the veterinary setting, either having been borrowed from human medicine or developed especially to address unmet veterinary needs, include imatinib, masitinib, and toceranib. Of these, the latter two have been approved for use in many parts of the world for the treatment of canine MCT. In many ways masitinib may be considered the forerunner in this field, with respect to history of regulatory authorisation and commercialisation, developmental progress of phase III clinical studies, and also in the depth and breadth of clinical knowledge acquired in both dogs and cats. It will be masitinib therefore, with its completed phase III studies in canine oncology and immune-mediate indications, its long-term follow-up of MCT treatment (approximately 6 years), and development program for numerous other canine and feline diseases that will serve as an example of what this remarkably versatile class of therapeutic drug promises to accomplish in veterinary medicine. We review the clinical development of masitinib in veterinary medicine to date, discuss safety-related issues, and emerging new therapeutic directions.
NEW THERAPEUTIC OPTIONS IN VETERINARY ONCOLOGY: TYROSINE KINASE INHIBITORS

Publication Category: Conference Presentation (Full manuscript available in appendices or upon request to AB Science - contact@ab-science.com)

Proceedings of the 2011 American College of Veterinary Internal Medicine Forum, June 15-18, Denver, USA. Technician Program (T44)
Albert Ahn

SUMMARY
Tyrosine kinase inhibitors (TKI), sometimes referred to as targeted therapies, have revolutionized the management of human cancer since the introduction of imatinib (Gleevec) in 2001. TKIs are now making inroads into veterinary medicine with mast cell tumors (MCT) being their first major success story. TKIs used in the veterinary setting, either having been borrowed from human medicine or developed especially to address unmet veterinary needs, include: imatinib, masitinib, and toceranib; of which the latter two have received regulatory registration in dogs with MCT. In many ways masitinib is the forerunner of such veterinary drug development; historically, developmentally, and also in the depth and breadth of clinical knowledge acquired. It will be masitinib therefore, with its completed phase III studies in canine oncology and immune-mediate indications, its long-term follow-up of MCT treatment, and development program for numerous other canine and feline oncology and non-oncological diseases that will serve as an example of what this remarkably versatile class of therapeutic drug promises to accomplish in veterinary medicine.
9.3 MASITINIB – THE EFFICACY OF TARGETED THERAPY IN VETERINARY MEDICINE

SUMMARY
Masitinib, a drug being developed for numerous indications in veterinary and human medicine by AB Science (www.ab-science.com), belongs to a therapeutic class known as targeted therapy. These small molecule drugs selectively inhibit specific tyrosine kinases or their signaling pathways. In the last decade several tyrosine kinase inhibitors (TKI) have been developed for the treatment of cancer and other diseases, the most well-known being imatinib (Gleevec, Novartis), which has dramatically improved the treatment for patients with chronic myelogenous leukemia and gastrointestinal stromal tumor. Unfortunately, resistance to imatinib tends to develop for some patients. Nonetheless, targeted therapies are still creating a buzz in human and veterinary medicine alike; including, at this year’s VCS conference in Las Vegas.

Masitinib is arguably the most specific inhibitor of KIT available. In vitro, it has shown greater affinity and selectivity for the KIT receptor as compared to imatinib, while not inhibiting, at therapeutic doses, those tyrosine kinases or tyrosine kinase receptors attributed to possible toxicity. This highly selective nature suggests that it will exhibit a better safety profile than other TKIs (Dubreuil et al, 2009). Among masitinib’s other claims-to-fame is that it was the first approved targeted therapy in veterinary oncology, having been registered by the European Medicine Agency in November 2008 for the treatment of non-resectable mast cell tumors (MCT)s grade II/III (EMEA approval under the trade name Masivet®; Kinavet® in the USA, pending FDA registration review).

Since Masivet’s European launch in 2009 it is estimated that 480 veterinarians have used it for approximately 1390 dogs; primarily as a treatment for MCT but also as an off-label treatment for various other cancers and in a phase III study for canine atopic dermatitis. In the USA, masitinib has been available as part of a compassionate-use program with approximately 650 recipients to date.
TARGETED THERAPY WITH MASITINIB IN CANINE AND FELINE TUMOURS IN TWO EUROPEAN VETERINARY ONCOLOGY CENTRES.

Publication Category: Conference Presentation (Full manuscript available in appendices or upon request to AB Science - contact@ab-science.com)

Johan de Vos and Malcolm Brearley

SUMMARY
Mast cell tumours are the most common malignant skin neoplasm of dogs. Their clinical behavior closely parallels their histopathological characteristics. The vast majority of Grade 1 MCTs are curable by relatively simple surgical excision; whereas the majority of poorly differentiated Grade 3 tumours require more extensive local therapy and have a high probability of metastatic spread. The majority of Grade 2 tumours do not metastasise and are theoretically curable by local therapy. However size and anatomical constraints may prevent this. Therefore although many MCTs are curable by surgery alone or in combination with radiation, there is a significant minority that pose a severe challenge to conventional treatment either because of extensive local disease or metastatic spread.

Recent studies indicated that gain-of-function mutations in the proto-oncogene c-kit are associated with canine mast cell tumour (MCT) development, correlating with a higher histologic grade and opening possibilities for therapeutic strategies. C-Kit, a trans-membrane tyrosine kinase, and its ligand Stem Cell Factor, have important signalling roles in normal mast cell development and function, erythropoiesis, lymphopoiesis, megakaryopoiesis, gametogenesis, and melanogenesis. Gain-of-function mutations cause a constitutive activation of the c-Kit receptor. So far it is not clear whether these mutations are causative for tumour development, or are only complicating the carcinogenesis. C-kit mutations are found in about 30% of canine MCT (predominantly high grade 2 and grade 3), without breed predilection. The majority of the mutations detected in canine MCT are internal tandem duplications, insertions and deletions in exon 11, the coding region of the JM domain. Mutations in exons 8 and 9, which encode for the fifth immunoglobulin-like domain, are less common.

Masitinib specifically targets the tyrosine kinase receptors c-Kit (wild type isoform as well as exon 8, 9 and 11 mutants), platelet-derived growth factor receptors (PDGFRα and β), and the intracellular kinases Lyn, Fyn and Lck. Masitinib competitively binds to the ATP-binding site of the intracellular kinase domain of the receptor, inhibiting phosphorylation and so activation of the receptor. The half-life of masitinib in dogs is 3-6 hours, and the recommended therapeutic canine dose is 12.5 mg/kg s.i.d. orally.

In De Ottenhorst, Veterinary Oncology Referral Centre, The Netherlands and The Queen’s Veterinary School Hospital, University of Cambridge, UK to date 38 tumour bearing dogs and 4 tumour bearing cats were treated with masitinib in the period December 2008 till December 2009. The main tumour type treated was MCT, but also dogs and cats with other tumour types were included.
9.5 DRUG-INDUCED MINIMAL CHANGE NEPHROPATHY IN A DOG

Publication Category: Peer Reviewed Journal (Full manuscript available in appendices or upon request to AB Science - contact@ab-science.com)


SUMMARY
This is a case report from the College of Veterinary Medicine, The University of Georgia. This report describes the clinical signs, laboratory and histopathologic abnormalities, and clinical course of drug-induced minimal change nephropathy in a dog.

9.6 CLINICAL TRIAL ON THE EFFICACY OF MASITINIB IN CANINE IBD

Publication Category: Peer Reviewed Journal

Procoli F.
Vet Rec. 2010 Nov 6;167(19):760. doi: 10.1136/vr.c6030

SUMMARY
IDIOPATHIC inflammatory bowel disease (IBD) is the most common cause of chronic intestinal disease in dogs. Current treatment protocols often involve the use of immunosuppressive doses of corticosteroids to reduce intestinal inflammation and achieve remission. However, a number of dogs with IBD treated with corticosteroids have either no response at all to the drug or relapse after weeks to months of treatment. In addition, treatment with prednisolone often results in unacceptable side effects. Masitinib is a protein tyrosine kinase inhibitor licensed for use in dogs with mast cell tumours, in which it has proven efficacy. There are reports that this drug can decrease inflammation in people with several immune-mediated disorders, including IBD. The Clinical Investigation Centre at the Royal Veterinary College is performing a clinical trial to evaluate the clinical efficacy of masitinib as sole treatment for canine IBD in steroid refractory cases over a period of eight weeks, and would welcome suitable cases. Requirements for enrolment in the trial include exclusion of other causes of chronic diarrhoea (through routine diagnostic tests), the presence of inflammatory cell infiltrates in mucosal biopsies obtained by gastroduodenoscopy and/or colonoscopy(for the diagnosis of IBD) and previous treatment with corticosteroids for at least four weeks with only minimal or no response. Consultation, physical examination, blood work and the costs of the drug will be covered. Please note that the drug will not be dispensed beyond the duration of the study.
Full copies of the following manuscripts are available as part of the appendices included in this document, or upon request to AB Science, or from the relevant publication source.

• Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

• Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study

• Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors

• Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors

• Masitinib is safe and effective for the treatment of canine mast cell tumors

• Masitinib for the treatment of canine atopic dermatitis: a pilot study

• Safety of masitinib mesylate in healthy cats

• Pharmacokinetics of masitinib in cats

• Masitinib – the efficacy of targeted therapy in veterinary medicine

• Drug-induced minimal change nephropathy in a dog

• Targeted therapy with masitinib in canine and feline tumours in two European veterinary oncology centres

• Masitinib decreases symptoms of canine atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial

• Masitinib – a targeted therapy with applications in veterinary oncology and inflammatory diseases

• New Therapeutic Options in Veterinary Oncology: Tyrosine Kinase Inhibitors

• Masitinib in Canine Mast Cell Disease